"PubmedID","Title","Publication Date","Non-academic Author(s)","Company Affiliation(s)","Corresponding Author Email"
"40053790","Augmenting Insufficiently Accruing Oncology Clinical Trials Using Generative Models: Validation Study.","2025 Mar 5","Mitsakakis N, Jonker E, Beltran-Bless AA, Mosquera L","CHEO Research Institute, Ottawa, ON, Canada., CHEO Research Institute, Ottawa, ON, Canada., CHEO Research Institute, Ottawa, ON, Canada., CHEO Research Institute, Ottawa, ON, Canada., CHEO Research Institute, Ottawa, ON, Canada.","N/A"
"40053445","Angular spatial compounding of diffraction corrected images improves ultrasound attenuation measurements.","2025 Mar 1","Czarnota GJ","QT Imaging Inc., Novato, California 94949, USA.","N/A"
"40051275","A plain language summary of the ASCERTAIN trial: oral decitabine and cedazuridine versus intravenous decitabine for MDS or CMML.","2025 Mar 6","Oganesian A, Keer HN, Azab M","wTaiho Oncology, Inc., Pleasanton, CA, USA (current affiliation; trial was conducted by Astex Pharmaceuticals, Inc., subsequently acquired by Taiho)., wTaiho Oncology, Inc., Pleasanton, CA, USA (current affiliation; trial was conducted by Astex Pharmaceuticals, Inc., subsequently acquired by Taiho)., xAstex Pharmaceuticals Inc. (now Taiho Oncology, Inc.), Pleasanton, CA, USA.","N/A"
"40050802","Engineered multifunctional nanoparticles for enhanced radiation therapy: three-in-one approach for cancer treatment.","2025 Mar 6","Toyang N, Lowe H","Flavocure Biotech Inc, Baltimore, Maryland, USA., Flavocure Biotech Inc, Baltimore, Maryland, USA.","tappidi1@jh.edu"
"40050768","CYP2D6 polymorphisms and endoxifen concentration in Chinese patients with breast cancer.","2025 Mar 6","Shi Y","Guangzhou Targene Biotech Company Ltd, Room 707, Block A, TengFei Street #1 Guangzhou Knowledge City, Huangpu District, Guangzhou, 600700, P. R. China. shaojianyong@targene.cn.","shaojianyong@targene.cn"
"40050524","Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.","2025 Mar 6","Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N","TerSera Therapeutics LLC, Deerfield, IL, USA., TerSera Therapeutics LLC, Deerfield, IL, USA., TerSera Therapeutics LLC, Deerfield, IL, USA., ConcertAI, LLC, Cambridge, MA, USA., ConcertAI, LLC, Cambridge, MA, USA., ConcertAI, LLC, Cambridge, MA, USA., ConcertAI, LLC, Cambridge, MA, USA., TerSera Therapeutics LLC, Deerfield, IL, USA.","kmccann@mednet.ucla.edu"
"40050354","Extended spectrum of cancers in PTEN hamartoma tumor syndrome.","2025 Mar 6","Yehia L, Plitt G, Joo J, Ni Y, Eng C","Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA. yehial@ccf.org., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Center for Immunotherapy and Precision Immuno-Oncology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.","yehial@ccf.org"
"40050276","Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.","2025 Mar 6","Arkenau T, Clack G, Bahl A, McIntosh S","Sarah Cannon Research Institute, London, UK., Carrick Therapeutics, Dublin, Ireland., Carrick Therapeutics, Dublin, Ireland., Carrick Therapeutics, Dublin, Ireland.","matthew.krebs@manchester.ac.uk"
"40050043","Immunosuppressive microenvironment of liver restrains chemotherapeutic efficacy in triple-negative breast cancer.","2025 Mar 6","N/A","Shanghai Shengdi Pharmaceutical Co Ltd, Shanghai, China zhouwenbin@njmu.edu.cn shwang@njmu.edu.cn pamghong@163.com liwei1218@njmu.edu.cn Zheng.pang@hengrui.com.","zhouwenbin@njmu.edu.cn"
"40049206","Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation.","2025 Mar","Young KH","Earle A Chiles Research Institute, Portland, OR, USA.","zmorris@humonc.wisc.edu"
"40048690","Recent Trends in Breast Cancer Mortality Rates for U.S. Women by Age and Race/Ethnicity.","2025 Mar 6","Monticciolo DL","Emeritus Faculty, Baylor Scott & White Central Texas Foundation for Imaging Research and Education, LLC, Temple, TX, USA.","N/A"
"40048260","Metabolic and transcriptional effects of bazedoxifene/conjugated estrogens in a model of obesity-associated breast cancer risk.","2025 Mar 6","Komm BS","Komm Pharma Consulting, LLC, San Francisco, United States of America.","N/A"
"40048009","Polycomb repressive complex 2 (PRC2) pathway's role in cancer cell plasticity and drug resistance.","2025 Mar 6","Heidari MM","Immunology Board for Transplantation and Cell-Based Therapeutics (Immunotact), Universal Scientific Education and Research Network (USERN), Tehran, Iran. medgenetic.1991@gmail.com.","medgenetic.1991@gmail.com"
"40046312","Revisiting the Need for Breast Imaging in Young Women with Clinically Significant Breast Pain and a Normal Physical Breast Examination.","2025 Mar 3","Grubstein A","Statistical Consulting Unit, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel.","N/A"
"40045925","Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha.","2025 Mar 6","N/A","Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.","N/A"
"40044045","AXL kinase inhibitor exhibits antitumor activity by inducing apoptotic cell death in triple-negative breast cancer cells.","2025 Mar 5","Kim SJ, Park YJ, Choi MJ","Axceso Biopharma Co., Ltd., Yongin, Republic of Korea., Axceso Biopharma Co., Ltd., Yongin, Republic of Korea., Axceso Biopharma Co., Ltd., Yongin, Republic of Korea.","suri28@hanyang.ac.kr"
"40040878","Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link.","2025 Feb","Uddin S","Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.","N/A"
"40038780","Anti-TGF-beta/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis.","2025 Mar 5","Zhang J, Zhou P","Wuhan YZY Biopharma Co., Ltd., Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, China., Wuhan YZY Biopharma Co., Ltd., Biolake, C2-1, No.666 Gaoxin Road, Wuhan, 430075, China.","borismq@163.com"
"40038137","Landscape of 2D Deep Learning Segmentation Networks Applied to CT Scan from Lung Cancer Patients: A Systematic Review.","2025 Mar 4","Safahi Z, Mousavi A, Farmani A, Yuan R, Rahmim A","Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada., Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada., Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada., Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada., Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada., Technological Virtual Collaboration (TECVICO Corp.), Vancouver, BC, Canada. msalman@bccrc.ca.","msalman@bccrc.ca"
"40037851","Anticancer Potential of Black Ginseng Extract in a Breast Cancer Cell Xenograft Mouse Model.","2025 Mar","Park HJ, Choi KT","Truth & Ginseng Biotechnology Research Co., Ltd., Jinan, Republic of Korea., Truth & Ginseng Biotechnology Research Co., Ltd., Jinan, Republic of Korea.","stlee76@kangwon.ac.kr"
"40036781","Cardio-oncology rehabilitation and exercise: evidence, priorities, and research standards from the ICOS-CORE working group.","2025 Feb 28","Adams SC","Cancer Fatigue Services Inc., Toronto, ON, Canada.","N/A"
"40036586","Evaluative Methodology for HRD Testing: Development of Standard Tools for Consistency Assessment.","2025 Feb 27","Zhang Z, Xu Z, Yang S, Li J, Wei L, Zheng Y","Precision Scientific (Beijing) Co., Ltd, Beijing 100085, China., Burning Rock Biotech, Guangzhou 510300, China., Amoy Diagnostics Co., Ltd, Xiamen 361027, China., Amoy Diagnostics Co., Ltd, Xiamen 361027, China., GeneWell Biotechnology Co., Ltd, Shenzhen 518081, China., GeneWell Biotechnology Co., Ltd, Shenzhen 518081, China.","N/A"
"40034958","The Role of HMGA1 and Height in Breast Cancer Risk and Prognosis: Insights from UK Biobank Data.","2025 Mar-Apr","Rheinstein PH","Severn Health Solutions, Severna Park, MD, U.S.A.","N/A"
"40034565","Adjuvant endocrine treatment strategies for non-metastatic breast cancer: a network meta-analysis.","2025 Mar","N/A","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.","N/A"
"40033418","Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer.","2025 Mar 3","Liu M, Wan X","Hunter Biotechnology, Inc., Hangzhou, 310051, China., Hunter Biotechnology, Inc., Hangzhou, 310051, China.","mx.liu@siat.ac.cn"
"40033028","Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.","2025 Mar 3","Raninga PV, Vittorio O, Khanna KK","QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. Prahlad.Raninga@mater.uq.edu.au., Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. KumKum.Khanna@mater.edu.edu.au.","Prahlad.Raninga@mater.uq.edu.au"
"40032400","Patients' and doctors' preferences in early-stage triple-negative breast cancer treatment in Asia-Pacific: a multi-territory discrete choice experiment using a cross-sectional survey.","2025 Mar 3","Hsu DC, Ihm SY, Tan EM, Qu S","MSD Asia Ltd, Hong Kong, Hong Kong., MSD Korea Ltd, Jung-gu, Seoul, Korea (the Republic of)., Real World Solutions, IQVIA Asia Pacific, Singapore., Real World Solutions, IQVIA, Shanghai, China.","yoland.antill@monash.edu"
"40030121","Undisclosed Conflicts of Interest in Japanese Cancer Clinical Trials: A Cross-Sectional Study of Author-Pharmaceutical Industry Financial Relationships.","2025 Mar 3","Saito H, Hakariya H","Medical Governance Research Institute, Tokyo, Japan., Medical Governance Research Institute, Tokyo, Japan., Medical Governance Research Institute, Tokyo, Japan.","N/A"
"40029182","Development, Characterization, and Therapeutic Utility of Paclitaxel-Resistant Breast and Gastric Cancer In Vitro and In Vivo Models.","2025 Mar","Tang F, Cui W, Ding F, Zhang Y, Qiang X, Gu Q, Wang D, Zhang Z","In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Nantong) Co, Ltd, Nantong, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Nantong) Co, Ltd, Nantong, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Nantong) Co, Ltd, Nantong, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Nantong) Co, Ltd, Nantong, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Nantong) Co, Ltd, Nantong, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China., In Vivo Pharmacology Unit, WuXi Biology, WuXi AppTec (Shanghai) Co, Ltd, Shanghai, China.","N/A"
"40027305","Circulating tumor DNA fraction predicts residual cancer burden post-neoadjuvant chemotherapy in triple negative breast cancer.","2024 Dec","Wang X, Bonora G, Blenman K","Predicine, Inc., Hayward, CA, USA., Predicine, Inc., Hayward, CA, USA., Predicine, Inc., Hayward, CA, USA., Predicine, Inc., Hayward, CA, USA., Predicine, Inc., Hayward, CA, USA.","N/A"
"40027235","ctDNA-based liquid biopsy reveals wider mutational profile with therapy resistance and metastasis susceptibility signatures in early-stage breast cancer patients.","2025 Mar","Bharde A, Dongare M, Hariramani K, Haldar S, Jadhav B, Jadhav V, Vasudevan A, Uttarwar M, Zhou W, Kishore S, Khandare J, Shafi G","OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India., OneCell Diagnostics, Wakad, Pune, 411057, India.","N/A"
"40026848","Extreme Nipple-Sparing Mastectomy: Feasibility of Nipple Preservation and Immediate Reconstruction in Breasts Weighing Over 600 Grams in a Cohort of 43 Patients.","2025","Li J","Cancer Institute, Allegheny Health Network Research Institute, Pittsburgh, Pennsylvania, USA.","N/A"
"40026705","Multifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Nonviral Gene Therapy.","2025 Feb 25","Pegoraro C, Masia Sanchis E, Huck-Iriart C","Principe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain., Principe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain., Principe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain., Principe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain., Principe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain.","N/A"
"40026293","Afadin loss induces breast cancer metastasis through destabilisation of E-cadherin to F-actin linkage.","2025 Mar 3","Ishiyama N","Launchpad Therapeutics, Inc, Cambridge, MA, USA.","N/A"
"40025964","Epidemiologic Studies of Biomarkers and Their Role in Carcinogenesis: The Need for a Formal Causal Inference Approach.","2025 Mar 3","Lynch BM","Clinical Epidemiology and Biostatistics Unit, Murdoch Children's Research Institute, Melbourne, Australia.","N/A"
"40025384","Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience.","2025 Mar 3","Brogi E","Laboratory Medicine and Molecular Diagnostics, Precision Diagnostics and Therapeutics Program, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.","weny@mskcc.org"
"40025017","Multimodal histopathologic models stratify hormone receptor-positive early breast cancer.","2025 Mar 2","Mane E, Dellapasqua S","MultiplexDX, Inc., One Research Court Suite 450, Rockville, MD, 20850, USA., MultiplexDX, Inc., One Research Court Suite 450, Rockville, MD, 20850, USA.","chandars@mskcc.org"
"40022692","Phallus indusiatus Extracts Promoted MCF-7 Apoptosis Under TNFalpha-induced Tumor Microenvironment by Attenuating NF-kappaB and Akt Activation.","2025 Feb 1","Choowongkomon K","AnonBiotec Inc, Patumthani 12120, Thailand.","N/A"
"40020876","AI-assisted detection of breast cancer lymph node metastases in the post-neoadjuvant treatment setting.","2025 Feb 26","Srinidhi C","Physical Sciences Platform, Sunnybrook Research Institute, Toronto, Ontario, Canada.","tonylt.xu@mail.utoronto.ca"
"40019493","Health-related quality of life in patients with HR+/HER2- early breast cancer treated with ribociclib plus a nonsteroidal aromatase inhibitor: results from the NATALEE trial.","2025 Feb 28","Yardley DA, Danyliv A","Sarah Cannon Research Institute, Nashville, TN, United States., Novartis Pharma AG, Basel, Switzerland.","N/A"
"40017634","Diagnosis and treatment of a rare bilateral primary thyroid cancer: a case report.","2024","Yan N, Guo T","Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China., Key Laboratory of Digital Technology in Medical Diagnostics of Zhejiang Province, Hangzhou, Zhejiang, China.","N/A"
"40017004","CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.","2025 Feb 27","Hamilton EP, Saini KS","Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Medical Oncology, Fortrea, Inc, Durham, NC, USA.","N/A"
"40016191","Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trial.","2025 Feb 28","Sun C, Zhang Q, Zou K, Dan M","CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, People's Republic of China., CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, People's Republic of China., CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, People's Republic of China., CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, Hebei, People's Republic of China.","xurh@sysucc.org.cn"
"40014172","Evolving strategies for the routine follow-up of patients with early breast cancer and the impact of COVID-19: a survey of healthcare providers.","2025 Feb 27","Pond G","Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.","mclemons@toh.ca"
"40013319","An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial.","2025 Feb 27","Wang L, Liu M, Duan X, Xu L","Clinical Science Department, Xuanzhu Biopharmaceutical Co., Ltd., Beijing, P. R. China., Clinical Science Department, Xuanzhu Biopharmaceutical Co., Ltd., Beijing, P. R. China., Clinical Science Department, Xuanzhu Biopharmaceutical Co., Ltd., Beijing, P. R. China., Clinical Science Department, Xuanzhu Biopharmaceutical Co., Ltd., Beijing, P. R. China.","N/A"
"40011694","Robust estimation of the intrinsic dimension of data sets with quantum cognition machine learning.","2025 Feb 26","Candelori L, Hogan CJ, Musaelian K, Samson R, Smith JET, Villani D, Wells MT","Qognitive, Inc., Miami Beach, FL, 33139, USA. luca.candelori@qognitive.io., Qognitive, Inc., Miami Beach, FL, 33139, USA., Qognitive, Inc., Miami Beach, FL, 33139, USA., Qognitive, Inc., Miami Beach, FL, 33139, USA., Qognitive, Inc., Miami Beach, FL, 33139, USA., Qognitive, Inc., Miami Beach, FL, 33139, USA., Qognitive, Inc., Miami Beach, FL, 33139, USA.","luca.candelori@qognitive.io"
"40011368","The impact of coadministration of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen.","2025 Feb 27","Loprinzi CL, Weinshilboum RM, Goetz MP","Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Division of Laboratory Genetics and Genomics, Personalized Genomics Laboratory, Mayo Clinic Laboratories, Mayo Clinic, Rochester, MN, USA., Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.","Goetz.Matthew@mayo.edu"
"40010039","The comparison of pupillometry to standard clinical practice for pain and preemptive analgesia before endotracheal suctioning: A randomized controlled trial.","2025 Feb 25","Bermudez-Ampudia C, Perez-Francisco I, Parraza-Diez N","Bioaraba Health Research Institute, Jose Atxotegi, Vitoria-Gasteiz 01009, Spain., Breast Cancer and Other Gynaecological Tumours Group, Bioaraba Health Research Institute, Vitoria-Gasteiz, Spain., Bioaraba Health Research Institute, Jose Atxotegi, Vitoria-Gasteiz 01009, Spain; Research Network on Chronicity, Primary Care and Health Promotion (RICAPPS), Madrid, Spain; Bioaraba, Primary Care, Epidemiology and Public Health Group, Vitoria-Gasteiz, Spain.","N/A"
"40009831","A role for NFIB in SOX2 downregulation and epigenome accessibility changes due to long-term estrogen treatment of breast cancer epithelial cells.","2025 Feb 26","Lado-Fernandez P, Mitchell JA","Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.","abatti.luis@gmail.com"
"40009771","Patterns of associations with epidemiologic factors by high grade serous ovarian cancer gene expression subtypes.","2025 Feb 26","Modugno F, Webb PM","Magee-Womens Research Institute, Pittsburgh, PA, United States., QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia.","N/A"
"40007999","Combined morphology and radiomics of intravoxel incoherent movement as a predictive model for the pathologic complete response before neoadjuvant chemotherapy in patients with breast cancer.","2025","Song Y","MR Research Collaboration Team, Siemens Healthineers Ltd., Shanghai, China.","N/A"
"40007480","Fluorescent p53 helix mimetics pairing anticancer and bioimaging properties.","2025 Feb 26","Vasita R","Analytical and Environmental Sciences Division and Centralized Instrumentation Facility, CSIR-Central Salt and Marine Chemicals Research Institute, Bhavnagar, 364002-India.","panchami.p@cug.ac.in"
"40007225","The Potent Antioxidant 3,5-Dihydroxy-4-Methoxybenzyl Alcohol Reveals Anticancer Activity by Targeting Several Signaling Pathways in Bone Metastatic Human Breast Cancer MDA-MB-231 Cells.","2025 Mar","Yoshiike K, Watanabe H, Watanabe M","Watanabe Oyster Laboratory Co. Ltd., Hachioji, Tokyo, Japan., Watanabe Oyster Laboratory Co. Ltd., Hachioji, Tokyo, Japan., Watanabe Oyster Laboratory Co. Ltd., Hachioji, Tokyo, Japan.","N/A"
"40006625","Understanding the Toxicity Profile of Approved ADCs.","2025 Feb 14","Ballestin P, Lopez de Sa A, Diaz-Tejeiro C, Paniagua-Herranz L, Sanvicente A, Lopez-Cade I, Perez-Segura P, Nieto-Jimenez C, Ocana A","Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain., Experimental Therapeutics Unit, Departamento Oncologia Medica, Instituto de Investigacion Sanitaria San Carlos (IdISSC), Hospital Clinico San Carlos (HCSC), 28040 Madrid, Spain.","N/A"
"40005991","Lignin-Based Nanocarrier for Simultaneous Delivery of (131)I and SN-38 in the Combined Treatment of Solid Tumors by a Nanobrachytherapy Approach.","2025 Jan 27","Warren B","Natural State Science LLC, 415 N. McKinley Street, Little Rock, AR 72205, USA.","N/A"
"40005359","Operational Advantages of Novel Strategies Supported by Portability and Artificial Intelligence for Breast Cancer Screening in Low-Resource Rural Areas: Opportunities to Address Health Inequities and Vulnerability.","2025 Jan 30","Xiques-Molina W, Lozada-Martinez ID","Research & Development Unit, Cure Latam Health Technologies, Barranquilla 080001, Colombia., Research & Development Unit, Cure Latam Health Technologies, Barranquilla 080001, Colombia.","N/A"
"40004162","Bone Marrow Origin of Mammary Phagocytic Intraductal Macrophages (Foam Cells).","2025 Feb 17","Mcphail K, Hoffman RM","Star Diagnostics Laboratories, 215 E Warm Springs Rd., Ste 108, Las Vegas, NV 89119, USA., AntiCancer, Inc., 7917 Ostow St., Suite B, San Diego, CA 92111, USA.","N/A"
"40004024","Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer.","2025 Feb 12","Rovira A","Cancer Research Program, IMIM (Hospital del Mar Research Institute), 08003 Barcelona, Spain.","N/A"
"40003896","Combining Sulfonylureas with Anticancer Drugs: Evidence of Synergistic Efficacy with Doxorubicin In Vitro and In Vivo.","2025 Feb 8","Golec M","Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Wybrzeze Armii Krajowej Street 15, 44-102 Gliwice, Poland.","N/A"
"40002257","COVID-19 Pandemic Conditions Affecting QoL and Mental Health of Oncology Patients in Poland.","2025 Feb 16","Meller J","Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.","N/A"
"40002228","Triple-Negative Breast Cancer Systemic Treatment: Disruptive Early-Stage Developments for Overcoming Stagnation in the Advanced Pipeline.","2025 Feb 13","Vethencourt A","Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain., Bellvitge Biomedical Research Institute (IDIBELL), 08908 Barcelona, Spain.","N/A"
"40002171","Prevalence of Homologous Recombination Repair Mutations and Association with Clinical Outcomes in Patients with Solid Tumors: A Study Using the AACR Project GENIE Dataset.","2025 Feb 8","Shao C, Zhou H, Chen C, Dettman EJ, Ren Y, Cristescu R, Gozman A, Jin F","Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA., Merck & Co., Inc., Rahway, NJ 07065, USA.","N/A"
"40001667","Plasticity of Expression of Stem Cell and EMT Markers in Breast Cancer Cells in 2D and 3D Culture Depend on the Spatial Parameters of Cell Growth; Mathematical Modeling of Mechanical Stress in Cell Culture in Relation to ECM Stiffness.","2025 Feb 4","Szostakowska-Rodzos M, Chmielarczyk M, Zacharska W, Fabisiewicz A, Kurzyk A, Mysliwy I, Kozaryna Z, Grzybowska EA","Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland., Molecular and Translational Oncology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Roentgena 5, 02-781 Warsaw, Poland.","N/A"
"40000910","An antibody-toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy.","2025 Feb 25","Lee D, Koong AC","Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USA., Fralin Biomedical Research Institute at VTC, Virginia Tech, Roanoke, VA, USA.","bykim@mdanderson.org"
"39999470","Breast cancer patients' experience of menopause care in the UK: thematic analysis of free-text comments.","2025 Feb 25","Seymour K, Newson L","Seymour Research Ltd, Devon, UK., Newson Health Ltd, Newson Health, Stratford-upon-Avon, UK.","N/A"
"39998766","Transient Lymphatic Remodeling Follows Sub-Ablative High-Frequency Irreversible Electroporation Therapy in a 4T1 Murine Model.","2025 Feb 25","Esparza S, Alinezhadbalalami N, Imran KM","Fralin Biomedical Research Institute at Virginia Tech-Carilion, Room 1210, 4 Riverside Circle, Roanoke, VA, 24016, USA., Fralin Biomedical Research Institute at Virginia Tech-Carilion, Room 1210, 4 Riverside Circle, Roanoke, VA, 24016, USA., Fralin Biomedical Research Institute at Virginia Tech-Carilion, Room 1210, 4 Riverside Circle, Roanoke, VA, 24016, USA., Fralin Biomedical Research Institute at Virginia Tech-Carilion, Room 1210, 4 Riverside Circle, Roanoke, VA, 24016, USA. Jm4kt@vt.edu.","Jm4kt@vt.edu"
"39996234","Dioxins do not only bind to AHR but also team up with EGFR at the cell-surface: a novel mode of action of toxicological relevance?","2025","Sondermann NC, Haarmann-Stemmann T","IUF - Leibniz Research Institute for Environmental Medicine, 40225 Dusseldorf, Germany., IUF - Leibniz Research Institute for Environmental Medicine, 40225 Dusseldorf, Germany.","N/A"
"39996124","Implementing a nurse-enabled, integrated, shared-care model involving specialists and general practitioners in early breast cancer post-treatment follow-up (EMINENT): a single-centre, open-label, phase 2, parallel-group, pilot, randomised, controlled trial.","2025 Mar","Ryan M","QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.","N/A"
"39995685","A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva(R)) in patients with bone metastasis from solid tumors.","2025 Apr","Zhuang P, Hu B, Hou Z, Su Z, Zheng S, Zhou M, Dou C","Shandong Boan Biotechnology Co., Ltd., PR China., Shandong Luye Pharmaceutical Co., Ltd., PR China., Shandong Boan Biotechnology Co., Ltd., PR China., Shandong Boan Biotechnology Co., Ltd., PR China., Shandong Luye Pharmaceutical Co., Ltd., PR China., Shandong Boan Biotechnology Co., Ltd., PR China., Shandong Boan Biotechnology Co., Ltd., PR China.","N/A"
"39995660","CD32B1, a versatile non-signaling antibody-binding scaffold for enhanced T cell adhesion to tumor stromal cognate antigens.","2025","Weinstein-Marom H, Avraham Y, Alon R","Laboratory of Immunology, MIGAL-Galilee Research Institute, Kiryat Shmona, Israel., Laboratory of Immunology, MIGAL-Galilee Research Institute, Kiryat Shmona, Israel., Laboratory of Immunology, MIGAL-Galilee Research Institute, Kiryat Shmona, Israel.","N/A"
"39993808","Methylation of ESRalpha Promoters in Benign Breast Tumors Could Be a Signature for Progression to Breast Cancer in African American Women.","2025 Mar-Apr","Naab TJ","Athari Biosciences, Sterling, VA, U.S.A.","ymkanaan@howard.edu"
"39992653","Neighborhood Environment, DNA Methylation, and Presence of Crown-Like Structures of the Breast.","2025 Feb 3","Bhawsar PMS, Jenkins BD","Molecular Digital Pathology Laboratory, Division of Cancer Epidemiology and Genetics, NCI, Leidos Biomedical Research Inc, Frederick, Maryland., Molecular Digital Pathology Laboratory, Division of Cancer Epidemiology and Genetics, NCI, Leidos Biomedical Research Inc, Frederick, Maryland.","N/A"
"39992612","Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice.","2025 Feb 24","Montalban-Casafont A","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.","japuig@clinic.cat"
"39991780","Pregnancy and pregnancy outcomes after adolescent and young adult cancer in the AYA horizon study.","2025 Feb 24","Smitherman AB","Redshift Technologies, Inc., New York, New York, USA., MedHealth Analytics Inc., Sugar Land, Texas, USA.","N/A"
"39990814","Design, synthesis, molecular docking and anticancer activity of benzothiazolecarbohydrazide-sulfonate conjugates: insights into ROS-induced DNA damage and tubulin polymerization inhibition.","2025 Feb 19","Omar MA","Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre Dokki 12622 Giza Egypt.","aladdinsrour@gmail.com"
"39990134","J-TAIL-2: A Prospective, Observational Study of Atezolizumab Combined With Carboplatin and Etoposide in Patients With Extensive-Stage SCLC in Japan.","2025 Mar","Kobayashi Y, Miwa A, Tanaka M","Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Chugai Pharmaceutical Co., Ltd., Tokyo, Japan., Chugai Pharmaceutical Co., Ltd., Tokyo, Japan.","N/A"
"39989783","Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration.","2025 Feb 18","Liljenback H, Airaksinen AJ, Roivainen A","Research and Development, Orion Pharma, Turku FI-20380, Finland., Research and Development, Orion Pharma, Turku FI-20380, Finland., Research and Development, Orion Pharma, Turku FI-20380, Finland.","N/A"
"39989041","Global perspectives on patient-centered outcomes: advancing patient-centered cancer clinical trials globally.","2025 Mar 1","Gopal S","Leidos Biomedical Research, Inc, Frederick, MD, United States.","N/A"
"39988770","Enhanced HER2 status detection in breast and gastric cancers using surrogate DNA methylation markers.","2025 Feb","Liu X, Li H, Liu H, Lu S, Lu Z, Chen Z, Pang D, Lin D","AnchorDx, Inc., Fremont, USA., AnchorDx Medical Co., Ltd., Guangzhou, China., AnchorDx Medical Co., Ltd., Guangzhou, China., AnchorDx Medical Co., Ltd., Guangzhou, China., AnchorDx Medical Co., Ltd., Guangzhou, China., AnchorDx, Inc., Fremont, USA., AnchorDx Medical Co., Ltd., Guangzhou, China., AnchorDx Medical Co., Ltd., Guangzhou, China.","N/A"
"39988443","[A Case Report of Lung Adenocarcinoma with EGFR G719A Mutation â€©and LMNA-NTRK1 Fusion].","2025 Jan 20","Yang Y, Luo W, Li Q, Zhuo T, Xiong W","Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China., Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China., Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China., Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China., Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China., Guangzhou Huayin Health Medical Group Co., Ltd, Guangzhou 510730, China.","N/A"
"39988329","Luminescent Biogenic Selenium Nanoparticles From Indigofera aspalathoides Vahl ex DC: A Novel Hepatoprotective Strategy for Enhancing Live(r) Health.","2025 Feb","Raman S, Chinnapandi B","ADRC Lifesciences Pvt. Ltd & Ashwanth Diagnostics and Research Centre, Madurai, Tamil Nadu, India., ADRC Lifesciences Pvt. Ltd & Ashwanth Diagnostics and Research Centre, Madurai, Tamil Nadu, India.","N/A"
"39987716","An injectable hydrogel for hemostasis and tumor suppression in intraoperative breast cancer.","2025 Feb 4","Lu W, Shang B","Xi'an Libang Pharmaceutical Co., Ltd, Xi'an, Shaanxi 710075, China., Xi'an Libang Pharmaceutical Co., Ltd, Xi'an, Shaanxi 710075, China.","lijianhui@spph-sx.ac.cn"
"39987084","Alternative splicing of transposable elements in human breast cancer.","2025 Feb 22","Beck CR","Immunoledge LLC, Montclair, NJ, 07042, USA.","alex.v.nesta@gmail.com"
"39985623","Genetic counseling referral rates and genetic testing outcomes in women with young breast cancer: a 20-year Canadian review.","2025 Feb 22","N/A","Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.","susan.randall@uhn.ca"
"39985481","Human herpesvirus-associated transposable element activation in human aging brains with Alzheimer's disease.","2025 Feb","Feng Y, Cao SQ","Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA., Program of Infectious Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA., Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA., Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.","N/A"
"39985094","Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers.","2025 Feb 21","N/A","Hunter Medical Research Institute, New Lambton, NSW, Australia.","k.hemminki@dkfz.de"
"39984762","Beyond the BRCA1/2 genes in ovarian cancer: the role of germline pathogenic variants in the ATM gene.","2025 Feb 21","Minucci A, Maneri G","Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli IRCCS, Rome, Italy., Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.","laura.demarchis@uniroma1.it"
"39984655","Intratumour oxidative hotspots provide a niche for cancer cell dissemination.","2025 Feb 21","Inoue M","Canon Inc., Ota-ku, Japan.","kiyonaka@chembio.nagoya-u.ac.jp"
"39979649","Treatment patterns and clinical outcomes in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer treated with chemotherapy: a large-scale data analysis using the Japanese claims database.","2025 Feb 20","Wang M","Real-World Evidence, Gilead Sciences Europe Ltd., Stockley Park, UK.","Takayuki.Kimura@gilead.com"
"39975513","Efficacy of goserelin in ovarian function suppression and preservation for pre- and perimenopausal breast cancer patients: a systematic review.","2025","Sayeed S, Cannon J, Osman N, Macrito R","TerSera Therapeutics, LLC, 520 Lake Cook Road, Deerfield, IL 60015, USA., TerSera Therapeutics, LLC, Deerfield, IL, USA., TerSera Therapeutics, LLC, Deerfield, IL, USA., TerSera Therapeutics, LLC, Deerfield, IL, USA.","N/A"
"39974646","Nanoparticle-Mediated mRNA Delivery to Triple-Negative Breast Cancer (TNBC) Patient-Derived Xenograft (PDX) Tumors.","2025 Feb 14","Akman A, Iroakazi CD, Cote M","Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada., Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada., Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada., Human Health Therapeutics Research Centre, National Research Council Canada, Ottawa K1A 0R6, Canada., Kidney Research Centre, Ottawa Hospital Research Institute, Ottawa, ON K1Y 1J8, Canada.","N/A"
"39973818","GABPalpha inhibits tumor progression and angiogenesis via a novel 18-bp indel within VEGF promoter in breast cancer.","2024 Dec","Li F","Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China.","N/A"
"39972950","Efficient Synthesis, Anticancer Evaluation of Triazole-Thiadiazole/Benzo[d]oxazole Scaffolds and Investigation of Their Reactivity Properties Using DFT Calculations and In silico Docking.","2025 Feb 19","Avuthu VSR","Dr Reddy's Laboratories Ltd, Medicinal Chemistry Division, Bachupally, Hyderabad, Hyderabad, INDIA.","N/A"
"39972941","Weight Gain Among Cancer Patients Receiving Chemotherapy-Facts and Numbers.","2025 Feb","Anker M","Baylor Scott and White Research Institute, Dallas, Texas, USA., Baylor Scott and White Research Institute, Dallas, Texas, USA.","N/A"
"39972552","Awareness of Financial Conflicts of Interest in Selecting Clinical Practice Guidelines Among Nepalese Oncologists: A Cross-Sectional Study.","2025 Feb","Ozaki A, Tsubokura M, Prasad Singh Y","Medical Governance Research Institute, Tokyo, Japan., Medical Governance Research Institute, Tokyo, Japan., Medical Governance Research Institute, Tokyo, Japan.","N/A"
"39972401","Density and entropy of immune cells within the tumor microenvironment of primary tumors and matched brain metastases.","2025 Feb 19","Preusser M","Precision Medicine Technologies, CBmed GmbH, Graz, Austria.","anna.berghoff@meduniwien.ac.at"
"39971965","Lessons learned from a candidate gene study investigating aromatase inhibitor treatment outcome in breast cancer.","2025 Feb 19","Dork T","Singapore Eye Research Institute, Singapore, Singapore.","reiner.hoppe@ikp-stuttgart.de"
"39970827","Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.","2025 Jan 26","Knafler G","Envision Pharma Group Fairfield CT USA.","Joseph.Sanderson@adaptimmune.com"
"39970544","Image quality and diagnostic performance of deep learning reconstruction for diffusion- weighted imaging in 3 T breast MRI.","2025 Feb 12","Paek M","Siemens Healthineers Ltd, Seoul, Korea.","ywchang@schmc.ac.kr"
"39967922","Outcomes of 32,019 Deep Inferior Epigastric Perforator Flap Reconstructions: Insights from the Largest National Readmission Data.","2025 Feb","Doremus N","Catalyst Medical Consulting, LLC, Simpsonville, SC.","N/A"
"39967859","Docetaxel-conjugated bile acid-derived nanomicelles can inhibit tumour progression with reduced toxicity.","2025 Feb 4","Dua C, Chakraborty R, Yadav P, Bajaj A","Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway Faridabad 121001 Haryana India bajaj@rcb.res.in., Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway Faridabad 121001 Haryana India bajaj@rcb.res.in., Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway Faridabad 121001 Haryana India bajaj@rcb.res.in., Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology NCR Biotech Science Cluster, 3rd Milestone, Faridabad-Gurgaon Expressway Faridabad 121001 Haryana India bajaj@rcb.res.in.","bajaj@rcb.res.in"
"39967196","Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy.","2025 Feb","Zhang D","Janssen Research and Development, LLC, Raritan, New Jersey, USA. Electronic address: dzhan107@its.jnj.com.","dzhan107@its.jnj.com"
"39966851","Management challenges of invasive breast carcinoma in a male patient who refused treatment: a case report.","2025 Feb 18","Makupa G","Kilimanjaro Clinical Research Institute, Moshi, Tanzania. alex.mremi@kcmuco.ac.tz.","alex.mremi@kcmuco.ac.tz"
"39966186","CHEK2-related breast cancer: real-world challenges.","2025 Feb 18","N/A","Translational Genomics and Targeted Therapies in Solid Tumors Group, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.","rsandoval.med@gmail.com"
"39965212","Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2-positive breast cancer.","2025 Feb 18","Vasaikar S","Clinical Biomarker and Diagnostics, Seagen, Bothell, Washington, USA.","N/A"
"39962816","YIGSR Functionalized Hybrid Exosomes Spatially Target Dasatinib to Laminin Receptors for Precision Therapy in Breast Cancer.","2025 Feb 17","Tiwari P, Shukla RP, Yadav K, Sharma M, Bakshi AK, Panwar D, Singh N, Agarwal N, Mugale MN, Mishra PR","Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Toxicology and Experimental Medicine, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India., Division of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Lucknow, Uttar Pradesh, 226031, India.","N/A"
"39962599","Assessing germline TP53 mutations in cancer patients: insights into Li-Fraumeni syndrome and genetic testing guidelines.","2025 Feb 17","Makarova M, Shigapova L, Gadzhieva S","Evogen LLC, Moscow, 115191, Russia., Life Improvement By Future Technologies (LIFT) Center, Skolkovo, Moscow, 143025, Russia., Life Improvement By Future Technologies (LIFT) Center, Skolkovo, Moscow, 143025, Russia., Evogen LLC, Moscow, 115191, Russia., Evogen LLC, Moscow, 115191, Russia.","a.danishevich@mknc.ru"
"39959749","Dietary isoflavone intake among breast cancer survivors and cancer-free women.","2025 Feb","Lee ES, Kim Z","Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea., Research Institute and Hospital, National Cancer Center, Goyang 10408, Korea.","N/A"
"39958058","The Multifaceted Role of lncRNA GAS5: A Pan-Cancer Analysis of Its Diagnostic, Prognostic, and Therapeutic Potential.","2025 Jan","Awad S","Epidemiology and Public Health, Tropical Medicine Research Institute, National Center for Research, Khartoum, SDN.","N/A"
"39955715","Cryo-Shocked Tumor-Reprogrammed Sonosensitive Antigen-Presenting Cells Improving Sonoimmunotherapy via T Cells and NK Cells Immunity.","2025 Feb 16","N/A","Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264000, China.","N/A"
"39955575","Computational development of mushroom-6-glucan/paclitaxel as a synergistic complementary medicine for breast cancer therapy.","2025 Feb 15","El-Deeb NM","Pharmaceutical Bioproducts Research Department, Genetic Engineering and Biotechnology Research Institute (GEBRI), City of Scientific Research and Technological Applications (SRTA-City), New Borg El- Arab City, Alexandria, Egypt. neldeeb@uottawa.ca., Nucleic Acids Research Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City), New Borg El-Arab City, Alexandria, Egypt.","neldeeb@uottawa.ca"
"39954697","Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.","2025 Mar","Bunge K, Song M, Livant E, Hillier SL","Magee-Womens Research Institute, Pittsburgh, PA, USA., Magee-Womens Research Institute, Pittsburgh, PA, USA., Magee-Womens Research Institute, Pittsburgh, PA, USA., Magee-Womens Research Institute, Pittsburgh, PA, USA.","lisa.noguchi@jhpiego.org"
"39954568","Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial.","2025 Feb 4","Yang F, Yu H, Li J, Wang Q, Zhu J","Shanghai Henlius Biotech, Inc., Shanghai, China., Shanghai Henlius Biotech, Inc., Shanghai, China., Shanghai Henlius Biotech, Inc., Shanghai, China., Shanghai Henlius Biotech, Inc., Shanghai, China., Shanghai Henlius Biotech, Inc., Shanghai, China.","xubinghe@medmail.com.cn"
"39953511","HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.","2025 Feb 14","N/A","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.","gilda.schmidt@uks.eu"
"39953121","Anisotropy visualisation from X-ray diffraction of biological apatite in mixed phase calcified tissue samples.","2025 Feb 14","Pinder SE","Diamond Light Source Ltd., Didcot, UK.","robert.scott@cranfield.ac.uk"
"39953097","Changes in long-term life expectancy and years of life lost following the Great East Japan Earthquake in Fukushima Prefecture.","2025 Feb 14","N/A","Research Institute of Science for Safety and Sustainability, National Institute of Advanced Industrial Science and Technology Tsukuba West, Tsukuba, Ibaraki, Japan.","h.saito0515@gmail.com"
"39952917","Matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory supporting metastasis.","2025 Feb 14","Maiques O, Varela A, Graziani V, Sewell J, Jung-Garcia Y, Albrengues J, Santacana M, Wallberg F","Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Quell Therapeutics, Translation & Innovation Hub, 84 Wood Ln, London, W12 0BZ, UK., Light Microscopy Facility, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Light Microscopy Facility, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK., Breast Cancer Research Bioinformatics Group, Chester Beatty Laboratories, London, SW3 6JB, UK., Cytoskeleton and metastasis Team, The Breast Cancer Now Toby Robins Research Centre Division of Breast Cancer Research, The Institute of Cancer Research, Chester Beatty Laboratories, London, SW3 6JB, UK. victoria.sanz-moreno@icr.ac.uk.","victoria.sanz-moreno@icr.ac.uk"
"39951671","Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing Study.","2025 Feb","Burganowski R, Rivera DR","Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA., Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA., Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA.","N/A"
"39951420","Hydrothermal treatment of yeast cell wall generates potent anti-proliferative agents targeting MCF7 breast cancer cells effectively even under culture conditions separated by a plastic wall.","2025","Kitagawa T","Agri Division and R&D Department, ASAHI BIOCYCLE CO.,LTD, Shibuya-ku, Tokyo, Japan.","N/A"
"39951047","Validation of the Skindex-16 questionnaire for assessing patient-reported outcomes in radiation dermatitis among breast cancer patients.","2025 Feb 14","Zhang L","MacroStat Inc, Toronto, ON, Canada.","Edward.Chow@sunnybrook.ca"
"39949747","Analysis of the diagnostic efficacy of ultrasound, MRI, and combined examination in benign and malignant breast tumors.","2025","Gao Z","the Research and Development Management Center of Anhui Fuqing Medical Equipment Co., Ltd., Hefei, China., the Research and Development Management Center of Anhui Fuqing Medical Equipment Co., Ltd., Hefei, China.","N/A"
"39948165","Clinical evaluation of breast cancer tissue with optical coherence tomography: key findings from a large-scale study.","2025 Feb 14","Feng C, Xu Q","BeiJing HealthOLight Technology Co., Ltd, Beijing, China., BeiJing HealthOLight Technology Co., Ltd, Beijing, China.","taiyanhong29@163.com"
"39947911","[(99m)Tc]Tc-MY6349 Probe for Trop2-Targeted SPECT Imaging: From Preclinical to Pilot Clinical Study.","2025 Feb 13","Zhu M, Wan Y","Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai, China., Shanghai Novamab Biopharmaceuticals Co., Ltd., Shanghai, China.","wangfan@bjmu.edu.cn"
"39946952","Comparative analysis of machine learning models for predicting pathological complete response to neoadjuvant chemotherapy in breast cancer: An MRI radiomics approach.","2025 Feb 12","Pane F","Breast Diagnostics Department - Humanitas Istituto Clinico Catanese, SP54 Contrada Cubba Marletta 11, Misterbianco 95045, Italy.","giuseppe.stella@dfa.unict.it"
"39946406","Understanding the aliya pulsed electric field dose-response relationship: Implications for ablation size, thermal load, and immune response in an orthotopic murine breast cancer model.","2025","Nafie EHO, Pastori C, Acharya R, Kaviani R, Hunter D, Shalaby W, Krimsky WS, Neal RE 2nd","Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America., Galvanize Therapeutics, Redwood City, CA, United States of America.","N/A"
"39946244","Social risk factors screening preferences among breast and prostate cancer survivors: A qualitative study.","2025 Feb 13","Schubel LC, Rivera Rivera J, Pratt-Chapman ML, Smith JL, King C","National Center for Human Factors in Healthcare, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Implementation Science; Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Implementation Science; Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., National Center for Human Factors in Healthcare, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., MedStar Institute for Quality and Safety, Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Implementation Science; Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA.","N/A"
"39946107","Endocrine Therapy Interruption, Resumption, and Outcomes Associated With Pregnancy After Breast Cancer.","2025 Feb 13","Ritter V, Wheeler AJ, Liang SY, Kenkare P, Gomez SL","Stanford Hospital/Technology and Digital Solutions/Research Technologies/Data Services, Stanford, California., Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California., Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California., Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California., Palo Alto Medical Foundation Research Institute, Sutter Health, Palo Alto, California.","N/A"
"39946089","Assessment of the benefits of bone modifying agents in the management of advanced breast, prostate, and lung cancers.","2025 Feb 14","N/A","Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.","N/A"
"39945311","First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors.","2025 Feb","Lee WS, Ock CY, Lee MJ, Bang J, Hong MJ, Roh EJ, Ha KS, Lim JH","Idience Co. Ltd., Seoul, Republic of Korea., Idience Co. Ltd., Seoul, Republic of Korea., Idience Co. Ltd., Seoul, Republic of Korea., Idience Co. Ltd., Seoul, Republic of Korea., Idience Co. Ltd., Seoul, Republic of Korea., Idience Co. Ltd., Seoul, Republic of Korea., Idience Inc., Irvine, California, USA., Ildong Pharmaceutical Co. Ltd, Gyeonggi-do, Republic of Korea.","N/A"
"39941823","Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.","2025 Jan 28","Schmitz H","Eisai Inc., Nutley, NJ 07110, USA.","N/A"
"39941714","The Role of Macrophages in Various Types of Tumors and the Possibility of Their Use as Targets for Antitumor Therapy.","2025 Jan 21","Dzhalilova D, Fatkhudinov T","Avtsyn Research Institute of Human Morphology, FSBSI Petrovsky National Research Centre of Surgery, 3 Tsyurupy Street, 117418 Moscow, Russia., Avtsyn Research Institute of Human Morphology, FSBSI Petrovsky National Research Centre of Surgery, 3 Tsyurupy Street, 117418 Moscow, Russia., Avtsyn Research Institute of Human Morphology, FSBSI Petrovsky National Research Centre of Surgery, 3 Tsyurupy Street, 117418 Moscow, Russia., Avtsyn Research Institute of Human Morphology, FSBSI Petrovsky National Research Centre of Surgery, 3 Tsyurupy Street, 117418 Moscow, Russia., Avtsyn Research Institute of Human Morphology, FSBSI Petrovsky National Research Centre of Surgery, 3 Tsyurupy Street, 117418 Moscow, Russia.","N/A"
"39941108","Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy.","2025 Feb 5","Chakraborty S","NE1 Inc., New York, NY 10022, USA.","N/A"
"39939471","Neutrophil-to-lymphocyte ratio is associated with accelerometer-measured physical activity levels in breast cancer survivors.","2025 Feb 12","Rosado Garcia S, Sanchez-Lopez AJ","Puerta de Hierro-Segovia de Arana Health Research Institute, IDIPHISA, Madrid, Spain., Puerta de Hierro-Segovia de Arana Health Research Institute, IDIPHISA, Madrid, Spain., Puerta de Hierro-Segovia de Arana Health Research Institute, IDIPHISA, Madrid, Spain., Puerta de Hierro-Segovia de Arana Health Research Institute, IDIPHISA, Madrid, Spain. arcasado@salud.madrid.org.","arcasado@salud.madrid.org"
"39939077","Nectin-4: A promising prognostic marker and therapeutic target in cancer.","2025","Kuttikrishnan S, Prabhu KS, Habeeba U, Mariyam Z","Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar., Translational Research Institute, Academic Health System, Hamad Medical Corporation, Doha, Qatar.","SKhan34@hamad.qa"
"39938393","Research progress of flavonoids targeting estrogen receptor in the treatment of breast cancer.","2025 Apr 1","Xiao H","Hunan Haopifu Pharmaceutical Co., Ltd, Hunan, China.","dengxpusc@163.com"
"39937302","A deep learning model to predict dose distributions for breast cancer radiotherapy.","2025 Feb 12","Bai L, Wang S, Liu Z","MedMind Technology Co. Ltd., AB 1920 Techart Plaza, Beijing, 100083, China., MedMind Technology Co. Ltd., AB 1920 Techart Plaza, Beijing, 100083, China., MedMind Technology Co. Ltd., AB 1920 Techart Plaza, Beijing, 100083, China.","liuzk2009@126.com"
"39937121","HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry.","2025 Feb 12","Wilcock D, Coleman JF, Kim JT, Affolter K, Jedrzkiewicz J, Cleary AS, Balatico M","ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US., ARUP Laboratories, Salt Lake City, Utah, US.","N/A"
"39937011","Three-Dimensional Models: Biomimetic Tools That Recapitulate Breast Tissue Architecture and Microenvironment to Study Ductal Carcinoma In Situ Transition to Invasive Ductal Breast Cancer.","2025 Feb 4","Osuala KO","Twelve Biosciences, Kalamazoo, MI 49009, USA.","N/A"
"39936988","Single-Cell RNA Sequencing on Formalin-Fixed and Paraffin-Embedded (FFPE) Tissue Identified Multi-Ciliary Cells in Breast Cancer.","2025 Jan 29","Palacios J, Lanza VF, Esteban-Rodriguez I","Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., UCA-GTB Unit, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain., Molecular Pathology of Cancer Group, Ramon y Cajal Health Research Institute (IRYCIS), 28034 Madrid, Spain.","N/A"
"39936424","Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.","2025 Feb 6","Mozafari MR","Biomaterials and Tissue Engineering Research Group, Interdisciplinary Technologies Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.","N/A"
"39935426","Optimizing therapeutic approaches for HR+/HER2- advanced breast cancer: clinical perspectives on biomarkers and treatment strategies post-CDK4/6 inhibitor progression.","2025","Ayala de la Pena F, Pages C","INCLIVA Biomedical Research Institute, Valencia 46010, Spain., CARE, the Translational Program in Cancer Research of Germans Trias i Pujol Research Institute (IGTP), Badalona 08916, Spain.","N/A"
"39934835","An IgE antibody targeting HER2 identified by clonal selection restricts breast cancer growth via immune-stimulating activities.","2025 Feb 12","Grandits M, Chauhan J, Partington L, Karagiannis SN, Bax HJ, FitzGerald K","Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK., Epsilogen Ltd, Waterfront, ARC West London, Manbre Road, Hammersmith, London, W6 9RH, UK. kevin@epsilogen.com.","kevin@epsilogen.com"
"39934484","Correction: Minimal residue disease detection in early-stage breast cancer: a review.","2025 Feb 11","Yuan X","Shuwen Biotech Co., Ltd., Moganshan National High tech Zone, Building 3, No. 333, Changhong Middle Street, Deqing, China., Shuwen Biotech Co., Ltd., Moganshan National High tech Zone, Building 3, No. 333, Changhong Middle Street, Deqing, China. yuanxy@shuwendx.com.","yuanxy@shuwendx.com"
"39934100","IRE1alpha: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer.","2025 Feb 12","N/A","Precision Cancer Medicine Theme, South Australian Health and Medical Research Institute (SAHMRI), Adelaide, SA, Australia.","nirmal.robinson@unisa.edu.au"
"39933898","Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping.","2025 Feb 10","Zhang Z","Pfizer Inc., San Diego, CA, United States of America.","carsten.denkert@uni-marburg.de"
"39933836","4-1BB agonist targeted to fibroblast activation protein alpha synergizes with radiotherapy to treat murine breast tumor models.","2025 Feb 11","Claus C, Tanos T, Klein C, Umana P","Roche Innovation Centre Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland., Roche Innovation Centre Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland., Roche Innovation Centre Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland., Roche Innovation Centre Zurich, Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.","mrruiz@unav.es"
"39932457","Characterization of plasma cell-free DNA variants as of tumor- or clonal hematopoiesis-origin in 16,812 advanced cancer patients.","2025 Feb 11","Cultrera J","Florida Cancer Specialists/Sarah Cannon Research Institute, United States.","N/A"
"39932300","Identification of intratumoral bacteria that enhance breast tumor metastasis.","2025 Feb 11","N/A","Michael Smith Genome Science Centre, BC Cancer Research Institute, Vancouver, British Columbia, Canada., Michael Smith Genome Science Centre, BC Cancer Research Institute, Vancouver, British Columbia, Canada., Michael Smith Genome Science Centre, BC Cancer Research Institute, Vancouver, British Columbia, Canada.","N/A"
"39932296","Evaluating the Radiation Sensitivity Index and 12-Chemokine Gene Expression Signature for Clinical Use in a CLIA Laboratory.","2025 Mar 1","Yoder SJ, Smith AT, Marchion DC, Qin D, Mule JJ","Advanced Diagnostic Laboratory, Moffitt Cancer Center & Research Institute, Tampa, Florida., Molecular Genomics Core, Moffitt Cancer Center & Research Institute, Tampa, Florida., Molecular Genomics Core, Moffitt Cancer Center & Research Institute, Tampa, Florida., Tissue Core, Moffitt Cancer Center & Research Institute, Tampa, Florida., Advanced Diagnostic Laboratory, Moffitt Cancer Center & Research Institute, Tampa, Florida.","N/A"
"39932272","Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.","2025 Feb 1","Reinhold WC, Elloumi F, Varma S, Wang Y, Rezai K, Morriset L, Huguet S, Luna A","Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., HiThru Analytics LLC, Princeton, New Jersey., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., ICF International Inc., Fairfax, Virginia., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland., Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland.","N/A"
"39930910","Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer.","2025 Feb 10","Kitadai R, Kuchiba A, Kojima Y, Sudo K, Fujiwara S, Tachibana K, Naito Y","Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Yokohama, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.","N/A"
"39930134","Natural compound PEITC inhibits gain of function of p53 mutants in cancer cells by switching YAP-binding partners between p53 and p73.","2025 Feb 10","Xu Q","Drug R&D Institute, JC (Wuxi) Company Inc., Wuxi, 214000, China. jcicom@163.com.","jcicom@163.com"
"39930063","Author Correction: Lymphatic collection and cell isolation from mouse models for multiomic profiling.","2025 Feb 10","Thangaswamy S","Legend Biotech, Somerset, NJ, USA.","jubellacker@hsph.harvard.edu"
"39929822","Spatial proximity of CD8(+) T cells to tumor cells predicts neoadjuvant therapy efficacy in breast cancer.","2025 Feb 10","Huang J, Zhang X","Panovue Biological Technology Co., Ltd, Beijing, 100000, China., Panovue Biological Technology Co., Ltd, Beijing, 100000, China.","Radisky.derek@mayo.edu"
"39928908","Progressive Myelitis in a 63-Year-Old Woman: A Case Report From the National Multiple Sclerosis Society Case Conference Proceedings.","2025 Mar","Cohen JA","Diagnostics Institute, Cleveland Clinic Foundation, OH.","N/A"
"39926099","Clinical Application of Artificial Intelligence in Ultrasound Imaging for Oncology.","2025 Jan 15","Teraya N, Harada N, Hamamoto R","Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan., Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan., Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan., Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan., HLPF Data Analytics Department, Fujitsu Ltd., Kawasaki, Japan., Division of Medical AI Research and Development, National Cancer Center Research Institute, Tokyo, Japan.","N/A"
"39926056","Change in Breast Cancer Screening Participation during COVID-19 Based on the 2019 and 2022 Comprehensive Survey of Living Conditions in Japan.","2025 Jan 15","N/A","Diabetes and Metabolism Information Center, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan.","N/A"
"39924718","Improving breast ultrasonography education: the impact of AI-based decision support on the performance of non-specialist medical professionals.","2024 Dec 12","Kim J, Yoon JH","BeamWorks Inc., Daegu, Korea., BeamWorks Inc., Daegu, Korea.","N/A"
"39924215","Institutional Variability in Ultrafast Breast MR Imaging: Comparing Compressed Sensing and View Sharing Techniques with Different Patient Populations and Contrast Injection Protocols.","2025 Feb 8","Iima M, Nakamoto Y","Division of Surgery, Kansai Electric Power Medical Research Institute, Osaka, Osaka, Japan., Division of Surgery, Kansai Electric Power Medical Research Institute, Osaka, Osaka, Japan.","N/A"
"39922806","Enhanced preoperative prediction of breast lesion pathology, prognostic biomarkers, and molecular subtypes using multiple models diffusion-weighted MR imaging.","2025 Feb 8","Zhang Y","MR Collaboration, Central Research Institute, United Imaging Healthcare, Shanghai, China.","aitao007@hotmail.com"
"39922153","Extracellular Vesicle-based Delivery of Paclitaxel to Lung Cancer Cells: Uptake, Anticancer Effects, Autophagy and Mitophagy Pathways.","2025 Feb 7","Rezaie J","Solid Tumor Research Center, Cellular and Molecular Medicine Research Institute, Urmia, Iran. Electronic address: Rezaie.j@umsu.ac.ir.","Rezaie.j@umsu.ac.ir"
"39921685","Breast cancer screening rates and influencing factors among LGBTQ groups in Japan.","2025 Feb 8","Hara A, Ozaki A","Medical Governance Research Institute, Minato, Tokyo, Japan., Medical Governance Research Institute, Minato, Tokyo, Japan. ozakiakihiko@gmail.com.","ozakiakihiko@gmail.com"
"39920848","Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells.","2025 Feb 7","Pathak K, Graff W, LeVee A, Pirrotte P, Mortimer J, Marcucci G","Early Detection and Prevention Division, Translational Genomics Research Institute, Phoenix, AZ, USA., Ostentus Therapeutics, Inc, Newport Coast, CA, USA., Division of Medical Oncology and Experimental Therapeutics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA., Early Detection and Prevention Division, Translational Genomics Research Institute, Phoenix, AZ, USA., Division of Medical Oncology and Experimental Therapeutics, Beckman Research Institute and City of Hope National Medical Center, Duarte, CA, USA., Early Detection and Prevention Division, Translational Genomics Research Institute, Phoenix, AZ, USA. lenguyen@coh.org.","lenguyen@coh.org"
"39920391","CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial.","2025 Feb 7","Shestova O, Ball M, Qureshi R, Schott BH, Sonawane P, DeLong SC, Christiano M, Swaby RF, Abramson S, Locke K, Barton D, Kennedy E, Gill S, Cushing D, Condamine T, Abdou Y","Sarah Cancer Research Institute, Nashville, TN, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA., Carisma Therapeutics, Philadelphia, PA, USA. Thomas.Condamine@carismatx.com.","Thomas.Condamine@carismatx.com"
"39920097","Clinical Assessment of the Drug-Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants.","2025 Feb 7","Zahir H, Murai M, Wu L, Valentine M, Hynes S","Biogen, Inc., Cambridge, MA, USA., Biogen, Inc., Cambridge, MA, USA., Biogen, Inc., Cambridge, MA, USA., Celerion, Inc., Tempe, AZ, USA., Biogen, Inc., Cambridge, MA, USA.","N/A"
"39917809","Gold Nanorods (GNRs): A Golden Nano Compass to Navigate Breast Cancer by Multimodal Imaging Approaches.","2025 Feb","Amalnerkar D, Chaudhari BP","Nanobioscience Group, Agharkar Research Institute, Pune, India., Nanobioscience Group, Agharkar Research Institute, Pune, India.","N/A"
"39917260","TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naive early-stage triple negative or HR-low/HER2- breast cancer.","2025","Andersen JC","Medical Oncology, Compass Oncology/Sarah Cannon Research Institute, Portland, OR, USA.","N/A"
"39915434","Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2- early breast cancer: a discrete choice survey study.","2025 Feb 7","Hazra NC, Meng Y","Analysis Group, Inc, London, UK., Analysis Group, Inc, London, UK.","erica_mayer@dfci.harvard.edu"
"39915198","Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis.","2025 Feb 5","Hernandez G","TriNetX LLC, Cambridge, Massachusetts, USA.","Sizheng.zhao@manchester.ac.uk"
"39915003","Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types.","2025 Feb 6","Subbiah V, Snider J, Bouzit L, Cho-Phan C, Price M, Li G, Quintanilha JCF, Huang RSP, Ross JS, Fabrizio D, Graf RP","Sarah Cannon Research Institute, Nashville, Tennessee, USA., Flatiron Health Inc, New York, New York, USA., Flatiron Health Inc, New York, New York, USA., Flatiron Health Inc, New York, New York, USA., Flatiron Health Inc, New York, New York, USA., Foundation Medicine Inc, Boston, Massachusetts, USA., Foundation Medicine Inc, Boston, Massachusetts, USA., Foundation Medicine Inc, Boston, Massachusetts, USA., Foundation Medicine Inc, Boston, Massachusetts, USA., Foundation Medicine Inc, Boston, Massachusetts, USA., Foundation Medicine Inc, San Diego, California, USA rgraf@foundationmedicine.com.","rgraf@foundationmedicine.com"
"39914664","Whole genome sequencing-powered ctDNA sequencing for breast cancer detection.","2025 Feb 4","Abbott CW, Boyle SM, Pugh J, Keough KC, Li B, Pyke RM, Navarro FCP, Chen RO","Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA., Personalis Inc., Fremont, USA.","nick.turner@icr.ac.uk"
"39912664","BRCA1-Associated Protein-1 Inactivated Melanoma Arising in a Pre-existing Nevus With ALK Fusion and Low Tumor Mutational Burden.","2025 Feb 6","Krishnan R, Dumur CI","Bernhardt Laboratories (A Sonic Healthcare Anatomic Pathology Practice), Jacksonville, FL., Bernhardt Laboratories (A Sonic Healthcare Anatomic Pathology Practice), Jacksonville, FL.","N/A"
"39912409","Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial-mesenchymal transition and tumor-infiltrating lymphocytes.","2025 Feb 6","van Marcke C","Center for Applied Molecular Technologies (CTMA), Institut de Recherche Experimentale et Clinique (IREC), UCLouvain, Brussels, Belgium., Pole of Pharmacology and Therapeutics (FATH), Institut de Recherche Experimentale et Clinique (IREC), UCLouvain, Brussels, Belgium.","N/A"
"39912214","Synthesis and Bioactivity of Selenium Nanoparticles From Tussilago farfara L. Polysaccharides: Antioxidant Properties and MCF-7 Cell Inhibition.","2025 Feb 6","Liu S, Wang J, Chen X","Shaanxi Kangruian Group Pharmaceutical Co. Ltd, Xi'an, Shaanxi, China., Shaanxi Kangruian Group Pharmaceutical Co. Ltd, Xi'an, Shaanxi, China., Shaanxi Kangruian Group Pharmaceutical Co. Ltd, Xi'an, Shaanxi, China.","N/A"
"39911089","Structural, Physicochemical, and Biological Insights into Novel (Acetylacetonate)(Oxydiacetato)Oxidovanadium(IV) Complexes with N-Containing Aromatic Compounds.","2025 Feb 6","Reghukmar S","QSAR Lab Ltd, Trzy Lipy 3, 80-172, Gdansk, Poland.","N/A"
"39910835","Reactivity of 2-((3-Cyano-4-(4-Fluorophenyl)-6-(Naphthalen-2-yl)Pyridin-2-yl)Oxy)Acetohydrazide Toward Some Reagents for Preparing a Promising Anticancer Agents and Molecular Docking Study.","2025 Feb 5","Khalaf HS, El-Manawaty MA, Kotb ER, Shamroukh AH","Photochemistry Department, Chemical Industries Research Institute, National Research Centre, Cairo, Egypt., Pharmacognosy Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Cairo, Egypt., Photochemistry Department, Chemical Industries Research Institute, National Research Centre, Cairo, Egypt., Photochemistry Department, Chemical Industries Research Institute, National Research Centre, Cairo, Egypt.","N/A"
"39910049","Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche.","2025 Feb 5","N/A","Johnson and Johnson Enterprise Innovations, Inc, Interventional Oncology, Spring House, PA, USA.","zhang_junfeng@gzlab.ac.cn"
"39909657","Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet.","2025 Feb","de Armas-Castellano A, Trujillo-Martin M","Canary Islands Health Research Institute Foundation, Santa Cruz de Tenerife, Tenerife, Spain., Canary Islands Health Research Institute Foundation, Santa Cruz de Tenerife, Tenerife, Spain; Network for Research on Chronicity, Primary Care, and Health Promotion, Madrid, Spain.","vincent.ribrag@gustaveroussy.fr"
"32965866","Mastalgia.","2025 Jan","Vadakekut ES","MVR Cancer Centre & Research Institute","N/A"
"39907850","Class-aware multi-level attention learning for semi-supervised breast cancer diagnosis under imbalanced label distribution.","2025 Feb 5","Wen R, Liu C, Feng R","China Comservice Enrising Information Technology Co., Ltd., Chengdu, Sichuan, 610041, China., China Comservice Enrising Information Technology Co., Ltd., Chengdu, Sichuan, 610041, China., China Comservice Enrising Information Technology Co., Ltd., Chengdu, Sichuan, 610041, China.","yfma2008@163.com"
"39907309","Retrospective Study of Genetic Testing Results Reveals Pathogenic Variants Beyond BRCA1/2 in Hereditary Breast and Ovarian Cancer Cases in New Brunswick: Implications for Future Care.","2025 Feb","Zhu YA","Atlantic Cancer Research Institute, Moncton, New Brunswick, Canada., Atlantic Cancer Research Institute, Moncton, New Brunswick, Canada.","N/A"
"39906658","Prioritizing breast cancer surgeries: insights from the KRONOS SCORE.","2024","Perez-Bartivas L, Camus JA, Morales Estevez C, Rioja P, De La Haba-Rodriguez J","Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain., Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Cordoba, Spain.","N/A"
"39905270","Assessment of Phage-Displayed Peptides Targeting Cancer Cell Surface Proteins: A Comprehensive Molecular Docking Study.","2025 Mar","Chakraborty S","Human Health Department, Central ADN Laboratories, Mexico City, Mexico.","N/A"
"39903940","Early Check-In Protocol: Identifying Medication Issues in Patients with Cancer at Health System Specialty Pharmacy.","2025 Feb 4","Wash A, Hutchinson K, Cash KJ, Giavatto C, Fitzpatrick C, Hunter A, Page O, Mourani J, Lopez-Medina AI","Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA., Outpatient Specialty, CPS Solutions, LLC (CPS), Dublin, OH, USA.","N/A"
"39903878","Preferences for Care Among African American Women Considering Postmastectomy Breast Reconstruction.","2025 Feb 4","N/A","Duke Clinical Research Institute, Durham, NC, USA.","N/A"
"39903842","Liquid Chromatography-High-Resolution Mass Spectroscopy-Based Metabolomics for Identification Cytotoxic Compounds From Acalypha Indica L. on MCF-7 Breast Cancer Cells as Potential Anticancer Agents.","2025 Feb 4","N/A","Tropical Biopharmaca Research Center, International Research Institute of Food, Nutrition, and Health, IPB Taman Kencana Campus, Jl Taman Kencana No. 3, Bogor, Indonesia.","N/A"
"39903492","The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors.","2025 Feb 4","Cardillo TM, Chou CC, Dornan C, Faris M","Gilead Sciences, Inc., Foster City, CA, United States., Gilead Sciences, Inc., United States., Gilead Sciences, Inc., United States., Gilead Sciences, Inc., United States.","N/A"
"39901917","A Global Survey of Self-Reported Cancer Screening Practices by Health Professionals for Kidney Transplant Candidates and Recipients.","2024","Lim WH, Teixeira-Pinto A, Boroumand F, Guha C, Hawley CM, Craig JC, Hassan D, Murakami N","Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia., Division of Nephrology, Kidney Research Centre, The Ottawa Hospital Research Institute, Ottawa, ON, Canada., Centre for Kidney Research, Kids Research Institute, The Children's Hospital at Westmead, Westmead, NSW, Australia.","N/A"
"39900053","[Dose banding. Observational study on cost optimization in chemotherapy].","2025","Sanguinetti JM","Laboratorio Integrador de Soluciones Pharma, Villa Lynch, Buenos Aires, Argentina. E-mail: sanguinetti.josema@gmail.com.","sanguinetti.josema@gmail.com"
"39900003","Pharmacological Characterization of GB1908, a Selective Galectin-1 Carbohydrate Binding Domain Inhibitor for the Treatment of Cancer.","2025 Feb 3","Herman KD, Holyer I, Humphries DC, Roper JA, Peterson K, Zetterberg FR, Pedersen A, MacKinnon AC, Slack RJ","Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark., Galecto Biotech AB, Copenhagen, Denmark.","N/A"
"39899036","Association between chemotherapy and the risk of developing breast cancer-related lymphedema: a nationwide retrospective cohort study.","2025 Feb 3","Chun SM, Choi M","National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Gyeonggi-Do, Republic of Korea., National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Gyeonggi-Do, Republic of Korea., National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Gyeonggi-Do, Republic of Korea., National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Gyeonggi-Do, Republic of Korea. magican1@snu.ac.kr.","magican1@snu.ac.kr"
"39896467","Phosphatidylserine (PS)-targeting chimeric Interferon (IFN) fusion proteins for anti-tumor applications.","2025 Jan 26","Kotenko SV","International Center for Public Health, Public Health Research Institute.","N/A"
"39896287","A bioprinted animal patient-derived breast cancer model for anti-cancer drug screening.","2025 Apr","N/A","Singapore Eye Research Institute, Singapore 169856, Singapore.","N/A"
"39894515","Spatial and temporal changes of breast-conserving surgery rates and its influential factors among Chinese patients with breast cancer from 2013 to 2019: a registry-based study.","2025 Feb 2","Yan Q, Huang X, Liang Z, Chen K","Health Data (Beijing) Technology Co Ltd, Guangzhou, China., Health Data (Beijing) Technology Co Ltd, Guangzhou, China., Health Data (Beijing) Technology Co Ltd, Guangzhou, China., Health Data (Beijing) Technology Co Ltd, Guangzhou, China., Health Data (Beijing) Technology Co Ltd, Guangzhou, China.","chenkai23@mail.sysu.edu.cn"
"39892541","Chemoenzymatic liquid-phase synthesis and immunogenic assessment of tumor-associated complex MUC1 glycopeptide variants.","2025 Apr","Chen D, Sui Q, Gao Q","Maxvax Biotechnology Co., LTD, Chengdu 610200, China., Maxvax Biotechnology Co., LTD, Chengdu 610200, China., Maxvax Biotechnology Co., LTD, Chengdu 610200, China.","lixia_kf@126.com"
"39891724","Blood-based prognostic scores and early dynamics under immunotherapy to select patients with metastatic solid tumors for continuing immune check-point inhibition: a prospective longitudinal study.","2025 Feb 1","Moreno D, Galvan P, Mellado B, Sauri T, Nogue M, Maurel J, Reig O, Sanfeliu E, Schettini F","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Immunology Service, Hospital Clinic of Barcelona, Clinic Foundation for Biomedical Research - August Pi I Sunyer Biomedical Research Institute (FCRB-IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Immunology Service, Hospital Clinic of Barcelona, Clinic Foundation for Biomedical Research - August Pi I Sunyer Biomedical Research Institute (FCRB-IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi I Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. schettini@recerca.clinic.cat.","jgcorbacho@ibima.eu"
"39890673","Diet quality and cardiometabolic health in breast cancer survivors: the Pathways Study.","2025 Feb 1","Kresovich JK","H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.","isaac.j.ergas@kp.org"
"39890170","Recombinant Methioninase (rMETase) Synergistically Sensitizes Ivermectin-resistant MCF-7 Breast Cancer Cells 9.9 Fold to Low-dose Ivermectin.","2025 Feb","Morinaga S, Kang BM, Hozumi C, Yamamoto N, Kimura H","AntiCancer Inc., San Diego, CA, U.S.A., AntiCancer Inc., San Diego, CA, U.S.A., AntiCancer Inc., San Diego, CA, U.S.A., AntiCancer Inc., San Diego, CA, U.S.A., AntiCancer Inc., San Diego, CA, U.S.A., AntiCancer Inc., San Diego, CA, U.S.A. all@anticancer.com.","all@anticancer.com"
"39889865","Undescribed diterpenes from Euphorbia mauritanica L. as modulators of the breast cancer resistance: Mechanistic and in silico studies.","2025 Jan 30","Allam RM","Pharmacology Department, Medical and Clinical Research Institute, National Research Centre, Dokki, Cairo, 12622, Egypt.","elshamynrc@yahoo.com"
"39889548","Isoxazole-pyrimidine derivatives as TACC3 inhibitors: A novel modality to targeted cancer therapy.","2025 Mar","Lim C, Vempati S","A2A Pharmaceuticals, Inc., 1185 Avenue of the Americas, New York, NY 10036, USA., A2A Pharmaceuticals, Inc., 1185 Avenue of the Americas, New York, NY 10036, USA.","banoglu@gazi.edu.tr"
"39887952","Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.","2025 Feb","Chen YL, Lee S, Yoshida K, Ufer M","Sumitomo Pharma America, Marlborough, Massachusetts, USA., Sumitomo Pharma America, Marlborough, Massachusetts, USA., Sumitomo Pharma Co. Ltd., Tokyo, Japan., Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.","N/A"
"39887653","Expression of Lymphoid Enhancer-Binding Factor 1 in Cancer-Associated Fibroblasts Mediates Tumor Growth and Transdifferentiation Toward Squamous Cell Carcinoma in Human Breast Cancer.","2025 Feb","Orimo A","Molecular Pathology and Genetics Division, Kanagawa Cancer Center, Research Institute, Kanagawa, Japan.","N/A"
"39887351","Clinical Evaluation of Drug-Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent.","2025 Jan 31","Peng CC, Humeniuk R, Raut A, Kwan A, Mak L, Stacom C, Xiao D, Chen S, Davies S, Madera S, Koullias Y, Lichtman A, Llewellyn J, Amini E, Winter H, Caro L","Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA., Gilead Sciences, Inc., Foster City, California, USA.","N/A"
"39886186","From prediction to practice: mitigating bias and data shift in machine-learning models for chemotherapy-induced organ dysfunction across unseen cancers.","2024","Al Moubayed N","Evergreen Life Ltd, Manchester, UK., Evergreen Life Ltd, Manchester, UK., Evergreen Life Ltd, Manchester, UK.","N/A"
"39886047","Metabolomics integrated genomics approach: Understanding multidrug resistance phenotype in MCF-7 breast cancer cells exposed to doxorubicin and ABCA1/EGFR/PI3k/PTEN crosstalk.","2025 Jun","Soltan MM","National Research Center, Biology Unit, Central Laboratory for Pharmaceutical and drug industries Research Institute, Chemistry of Medicinal Plants Department, Al Bohouth Street, Dokki, Egypt.","N/A"
"39885684","Reporting and representation of participant race and ethnicity in phase III clinical trials for solid tumors.","2025 Dec","Wang T, Villanueva DJ, Gifkins D","Janssen Research & Development LLC, Raritan, NJ, USA., Janssen Research & Development LLC, Miami, FL, USA., Janssen Research & Development LLC, Raritan, NJ, USA.","N/A"
"39885132","Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer.","2025 Jan 30","Stewart SA","Leap Therapeutics, Cambridge, MA, USA.","faccior@wustl.edu"
"39884822","Efflux transporters in drug disposition during pregnancy.","2025 Jan","Han LW, Liao MZ, Neradugomma NK, Zhang Y","Genentech, Inc, South San Francisco, California., Genentech, Inc, South San Francisco, California., Novartis Institute of Biomedical Research Inc, Cambridge, Massachusetts., Schrodinger Inc, New York, New York. Electronic address: yie.elaine@gmail.com.","yie.elaine@gmail.com"
"39884812","Absolute membrane protein abundance of P-glycoprotein, breast cancer resistance protein, and multidrug resistance proteins in term human placenta tissue and commonly used cell systems: Application in physiologically based pharmacokinetic modeling of placental drug disposition.","2025 Jan","Abduljalil K","Certara Predictive Technologies, Sheffield, United Kingdom.","Zubida.al-majdoub@manchester.ac.uk"
"39883436","Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer: The ALEXANDRA/IMpassion030 Randomized Clinical Trial.","2025 Jan 30","Chui SY, Dieterich M, Perretti T, Shearer-Kang E, Molinero L","Genentech Inc, South San Francisco, California., F. Hoffmann-La Roche Ltd, Basel, Switzerland., F. Hoffmann-La Roche Ltd, Basel, Switzerland., Genentech Inc, South San Francisco, California., Genentech Inc, South San Francisco, California.","N/A"
"39882028","Hydroxytyrosol, a Component of Olive Oil for Breast Cancer Prevention in Women at High Risk of Cancer.","2025","Zhao H, Wong S","Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas, USA., Houston Methodist Research Institute, Weill Cornell Medicine, Houston, Texas, USA.","N/A"
"39877554","SPIRIT-DEFINE explanation and elaboration: recommendations for enhancing quality and impact of early phase dose-finding clinical trials protocols.","2025 Jan","N/A","Strategic Consulting, Cytel (Australia), Perth, WA, Australia.","N/A"
"39876847","Current Practices and Trends of Plastic and Oncoplastic Breast Surgeons in Canada.","2025 Feb","Zeitouni C","Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.","N/A"
"39875558","Semi-mechanistic efficacy model for PARP + ATR inhibitors-application to rucaparib and talazoparib in combination with gartisertib in breast cancer PDXs.","2025 Mar","Zenke FT, Bolleddula J","EMD Serono Research & Development Institute, Inc., Billerica, MA, USA., EMD Serono Research & Development Institute, Inc., Billerica, MA, USA.","cchassagnole@physiomics.co.uk"
"39875376","Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study.","2025 Jan 29","N/A","Genecast Biotechnology Co.Ltd., Wuxi, China., Genecast Biotechnology Co.Ltd., Wuxi, China., Genecast Biotechnology Co.Ltd., Wuxi, China.","yuzhigang@sdu.edu.cn"
"39873699","Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors.","2025 Jan 3","Laurent CA","Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, WA, United States.","N/A"
"39873419","Analyzing free fatty acids in seminal plasma from asthenozoospermia patients undergoing antioxidant therapy.","2025 Jan 28","Agharezaee N, Gilany K","LogixX Pharma, Theale, Berkshire, United Kingdom., Monoclonal Antibody Research Center, Avicenna Research Institute (ACECR), Tehran, Iran.","N/A"
"39871392","CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 - metastatic breast cancer.","2025 Jan 27","Makari D, McCaleb R, Arias I, Stergiopoulos S, Li B","Pfizer Inc, New York, NY, USA., Pfizer Inc, New York, NY, USA., Pfizer Inc, New York, NY, USA., Pfizer Inc, New York, NY, USA., Pfizer Inc, New York, NY, USA.","susan_dent@urmc.rochester.edu"
"39869307","Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers.","2025 Jan 27","Sokolowski KA, Tse BW, Rogers R","Translational Research Institute, Brisbane, QLD, Australia., Translational Research Institute, Brisbane, QLD, Australia., Mater Research Institute, Brisbane, QLD, Australia.","N/A"
"39868978","Novel Strategy of Antibody Affinity Maturation and Enhancement of Nucleolin-Mediated Antibody-Dependent Cellular Cytotoxicity Against Triple-Negative Breast Cancer.","2025 Jan","Moreira JN","Pathogen Genome Bioinformatics and Computational Biology, Research Institute for Medicines (iMed.ULisboa), Faculdade de Farmacia, Universidade de Lisboa, Lisboa, Portugal.","N/A"
"39868490","LIG1 is a synthetic lethal target in BRCA1 mutant cancers.","2025 Jan 27","Martires LCM, Ahronian LG, Pratt CB, Zhang X, Whittington DA, Zhang H, Shen B, Come J, McCarren P, Liu MS, Min C, Feng T, Jahic H, Ali JA, Li F, Andersen JN, Huang A, Mallender WD, Nicholson HE","Tango Therapeutics, Cambridge, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics, Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics, Cambridge, MA, United States., Tango Therapeutics, Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., KSQ Therapeutics, Lexington, MA, United States., Tango Therapeutics, Cambridge, MA, United States., Tango Therapeutics (United States), Boston, Massachusetts, United States., Tango Therapeutics, Boston, MA, United States., Tango Therapeutics (United States), Boston, MA, United States., Tango Therapeutics (United States), Boston, United States.","N/A"
"39868374","EIF4A3-induced circ_0022382 promotes breast cancer cell progression through the let-7a-5p/PI3K/AKT/mTOR signaling pathway and SLC7A11 axis.","2024","Zhang J, Sun X","HEALTH BioMed Research & Development Center, Health BioMed Co., Ltd., Ningbo, Zhejiang, China., HEALTH BioMed Research & Development Center, Health BioMed Co., Ltd., Ningbo, Zhejiang, China., HEALTH BioMed Research & Development Center, Health BioMed Co., Ltd., Ningbo, Zhejiang, China.","N/A"
"39866038","Changes in HER2 Amplification Status for Breast Cancer Patients After Immunohistochemistry Directed In Situ Hybridization.","2025 Mar 1","Beech C, Moore KH, Rowe L, Mahlow J, Jedrzkiewicz J, Lomo L, Gering M, Maughan M, Davis R, Albertson DJ, Adelhardt P, Kim J, Coleman JF, Deftereos G, Gulbahce EH","Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories., Institute for Experimental Pathology, ARUP Laboratories.","N/A"
"39865983","Therapeutic alliance in a stepped digital psychosocial intervention for breast cancer patients: findings from a multicentre randomised controlled trial.","2025 Jan 27","Juan-Linares E, Serra-Blasco M, Ciria-Suarez L","Psychooncology and Digital Health Group, The Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Spain; and Psycho-oncology Unit, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., ICOnnecta't Digital Health Program, Catalan Institute of Oncology, Hospitalet del Llobregat, Spain; Psychooncology and Digital Health Group, The Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Spain; and Carlos III Health Institute, Mental Health Networking Biomedical Research Centre (CIBERSAM), Madrid, Spain., ICOnnecta't Digital Health Program, Catalan Institute of Oncology, Hospitalet del Llobregat, Spain; and Psychooncology and Digital Health Group, The Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Spain.","N/A"
"39865831","ZNF165: A Pan-Cancer Biomarker with Prognostic and Therapeutic Potential.","2025 Jan 24","Lyu G, Li D","Scientific Research Center, Dongguan Labway Medical Testing Laboratory Co., Ltd., Dongguan, 523429, China., Scientific Research Center, Beijing ChosenMed Clinical Laboratory Co., Ltd. 101, 1F, Building 3, No.156 Jinghai 4th Road, Beijing Economic and Technological Development Zone, Beijing, 100176, China.","N/A"
"39865220","Clinical relevance of macromolecular complexes involving integrins, potassium and sodium ion channels and the sodium/proton antiporter in human breast cancer.","2025 Jan 26","Djamgoz MBA","MCK Therapeutics Srl, Pistoia, Italy., MCK Therapeutics Srl, Pistoia, Italy.","elena.lastraioli@unifi.it"
"39864598","Human organotypic colon in vitro microtissue: unveiling a new window into colonic drug disposition.","2025 Jan 24","Markus J, Evers R","MatTek In Vitro Life Science Laboratories, Bratislava, Slovak Republic., Preclinical Sciences & Translational Safety, Janssen R&D, LLC, Spring House, Pennsylvania, USA.","skourula@its.jnj.com"
"39864054","A case of Li-Fraumeni syndrome caused by a 3.6 kb deletion in the TP53 gene suggested by additional data from the NCC Oncopanel.","2025 Jan 26","Souma S, Yamaguchi K, Fujimori H, Asano N, Ohnuki K","Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan., Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan., Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan., Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan., Division of Cancer Stem Cell, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan., Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, 47-1 Nodayama, Medeshima-Shiode, Natori, Miyagi 981-1293, Japan.","N/A"
"39862785","Estrogenic and anti-estrogenic assessment of the flame retardant, 2-ethylhexyl diphenyl phosphate (EHDPP), and its metabolites: Evidence from in vitro, in silico, and transcriptome studies.","2025 Jan 20","Tachachartvanich P, Sangsuwan R, Navasumrit P, Ruchirawat S, Ruchirawat M","Laboratory of Environmental Toxicology, Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology (EHT), OPS, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand; Program in Environmental Toxicology, Chulabhorn Graduate Institute, Bangkok 10210, Thailand., Laboratory of Natural Products, Chulabhorn Research Institute, Bangkok 10210, Thailand., Laboratory of Environmental Toxicology, Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology (EHT), OPS, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand; Program in Environmental Toxicology, Chulabhorn Graduate Institute, Bangkok 10210, Thailand., Center of Excellence on Environmental Health and Toxicology (EHT), OPS, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand; Laboratory of Medicinal Chemistry, Chulabhorn Research Institute, Bangkok 10210, Thailand; Program in Chemical Sciences, Chulabhorn Graduate Institute, Bangkok 10210, Thailand., Laboratory of Environmental Toxicology, Chulabhorn Research Institute, Bangkok 10210, Thailand; Center of Excellence on Environmental Health and Toxicology (EHT), OPS, Ministry of Higher Education, Science, Research and Innovation, Bangkok, Thailand. Electronic address: mathuros@cri.or.th.","mathuros@cri.or.th"
"39861690","Liposomal Formulation of Hydroxychloroquine Can Inhibit Autophagy In Vivo.","2024 Dec 30","N/A","Cuprous Pharmaceuticals Inc., Vancouver, BC V6T 1Z3, Canada., Cuprous Pharmaceuticals Inc., Vancouver, BC V6T 1Z3, Canada.","N/A"
"39859207","Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine-Biology Is Still King.","2025 Jan 9","Ramaswamy H, Chmielewski-Stivers N, Menicucci A, Audeh W","Agendia Inc., Irvine, CA 92618, USA., Agendia Inc., Irvine, CA 92618, USA., Agendia Inc., Irvine, CA 92618, USA., Agendia Inc., Irvine, CA 92618, USA.","N/A"
"39857996","XGBoost Enhances the Performance of SAFE: A Novel Microwave Imaging System for Early Detection of Malignant Breast Cancer.","2025 Jan 10","Yurtseven A, Cayoren M, Bugdayci O","Mitos Medical Technologies, ITU Ayazaga Ari 1, Maslak, 34469 Istanbul, Turkey., Mitos Medical Technologies, ITU Ayazaga Ari 1, Maslak, 34469 Istanbul, Turkey., Mitos Medical Technologies, ITU Ayazaga Ari 1, Maslak, 34469 Istanbul, Turkey., Mitos Medical Technologies, ITU Ayazaga Ari 1, Maslak, 34469 Istanbul, Turkey., Mitos Medical Technologies, ITU Ayazaga Ari 1, Maslak, 34469 Istanbul, Turkey.","N/A"
"39857981","Evaluating the Quality of Real-World Data on Adherence to Oral Endocrine Therapy in Breast Cancer Patients: How Real Is Real-World Data?","2025 Jan 9","Espinas JA, Martinez-Soler F, Tibau A","Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain., Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.","N/A"
"39857957","Differential Response to Local Stimulator of Interferon Genes Agonist Administration in Tumors with Various Stimulator of Interferon Genes Statuses.","2025 Jan 8","Drzyzga A, Czapla J, Matuszczak S, Lasut-Szyszka B, Cichon T, Pilny E, Jarosz-Biej M, Smolarczyk R","Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland., Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, 44-102 Gliwice, Poland.","N/A"
"39857048","Concurrent Viewing of H&E and Multiplex Immunohistochemistry in Clinical Specimens.","2025 Jan 13","Morrison LE, Larrinaga TM, Kelly BD, Lefever MR, Beck RC, Bauer DR","Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA., Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA., Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA., Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA., Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA., Roche Diagnostics Solutions (Ventana Medical Systems, Inc.), 1910 E. Innovation Park Dr., Tucson, AZ 85755, USA.","N/A"
"39856067","Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.","2025 Jan 24","Lee A","Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillmann Cancer Center, Pittsburgh, PA, USA., Women's Cancer Research Center, Magee-Womens Research Institute, UPMC Hillmann Cancer Center, Pittsburgh, PA, USA. oesterreichs@upmbc.edu.","parejaf@mskcc.org"
"39854815","Enhancing lesion detection in automated breast ultrasound using unsupervised multi-view contrastive learning with 3D DETR.","2025 Apr","Cao Y","Shenzhen RayShape Medical Technology Co., Ltd, Shenzhen, China.","ruobing.huang@szu.edu.cn"
"39853667","Efficacy and safety of JMT103 in patients with bone metastases from solid tumors: A randomized Phase Ib clinical trial.","2025 Jan 23","Yuan J, Wang J, Li H","CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China., CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China., CSPC ZhongQi Pharmaceutical Technology (Shijiazhuang) Co., Ltd., Shijiazhuang, China.","N/A"
"39851557","Association of Structural Maintenance of Chromosome-1A Phosphorylation with Progression of Breast Cancer.","2025 Jan 17","Kowolik CM, Horne DA","Diabetes and Metabolism Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA., Diabetes and Metabolism Research Institute, City of Hope National Medical Center, Duarte, CA 91010, USA.","N/A"
"39851103","Harnessing Therapeutic Potential of Allicin Against Cancer: An Exploratory Review.","2025 Jan 23","Saini A, Saini V, Dhingra AK","Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, 135133, Haryana, India., Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, 135133, Haryana, India., Global Research Institute of Pharmacy, Radaur, Yamuna Nagar, 135133, Haryana, India.","N/A"
"39850402","Enhancing diagnostic accuracy in breast cancer: integrating novel machine learning approaches with enhanced image preprocessing for improved mammography analysis.","2024","Mehrabi M, Salek N","Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran., Nuclear Fuel Research School, Nuclear Science and Technology Research Institute, Tehran, Iran.","N/A"
"39850119","Yavar-70A, a novel water-in-oil adjuvant: A potency study in HPV-16E7d vaccine model.","2025","Hassanzadeh SM","Poultry Viral Vaccines Research and Production Department, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization(AREEO), Karaj, Iran.","N/A"
"39849600","Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]).","2025 Jan 23","Zdenkowski N, Singer CF, Theall KP, Fesl C","Alliance Foundation Trials (AFT) LLC, Boston, MA, USA., Alliance Foundation Trials (AFT) LLC, Boston, MA, USA., Alliance Foundation Trials (AFT) LLC, Boston, MA, USA., Alliance Foundation Trials (AFT) LLC, Boston, MA, USA., Alliance Foundation Trials (AFT) LLC, Boston, MA, USA., Alliance Foundation Trials (AFT) LLC, Boston, MA, USA.","Angela.demichele@pennmedicine.upenn.edu"
"39847203","A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy +/- targeted therapy in HR + HER2-negative advanced breast cancer.","2025 Jan 23","Guillemette S, Leite R, Caron MA","Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada., Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada., Novartis Pharmaceuticals Canada Inc., Montreal, QC, Canada.","schia@bccancer.bc.ca"
"39846590","Development, Validation, and Application of the Paya Hamsan Technologies Underivatized Newborn Screening Assay (PHUNSA) for Inborn Metabolic Disorders in Dried Blood Spot Samples from Iranian Infants.","2025 Jan 8","N/A","Reproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran 1983969412, Iran.","N/A"
"39845722","Quantitative immunohistochemistry analysis of breast Ki67 based on artificial intelligence.","2024","Chen B, Wang Q, Gui K","Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China., Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China., Ningbo Konfoong Bioinformation Tech Co., Ltd, Ningbo, China.","N/A"
"39844441","Three-dimensional complementary breast ultrasound (3D CBUS): Improving 3D spatial resolution uniformity with orthogonal images.","2025 Jan 22","Aziz A, Bax JS, Gardi L, Fenster A","Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada., Robarts Research Institute, London, Ontario, Canada.","N/A"
"39844110","Multimodal treatments and the risk of breast cancer-related lymphedema: insights from a nationally representative cohort in South Korea.","2025 Jan 22","Chun SM","National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Republic of Korea., National Traffic Injury Rehabilitation Research Institute, National Traffic Injury Rehabilitation Hospital, Yangpyeong, 12564, Republic of Korea. Jaho.leigh@gmail.com.","Jaho.leigh@gmail.com"
"39844055","Tousled-like kinase loss confers PARP inhibitor resistance in BRCA1-mutated cancers by impeding non-homologous end joining repair.","2025 Jan 22","Kim MA, Kim B, Jeon J, Lee J, Jang H, Baek M, Shin D","Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea., Research Institute, National Cancer Center, Goyang-Si, Gyeonggi-Do, 10408, Republic of Korea. kylee@ncc.re.kr.","kylee@ncc.re.kr"
"39843795","Lutetium-177 labeled iPD-L1 as a novel immunomodulator for cancer-targeted radiotherapy.","2025 Jan 22","Melendez-Alafort L","Immunology and Molecular Oncology Diagnostics Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy. laura.melendezalafort@iov.veneto.it.","laura.melendezalafort@iov.veneto.it"
"39843429","Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitors.","2025 Jan 22","Kan Z, Wen J, Bonato V, Webster J, Yang W, Ivanov V, Kim KH, Roh W, Liu C, Mu XJ, Lapira-Miller J, Oyer J, VanArsdale T, Rejto PA, Bienkowska J","Oncology Research & Development, Pfizer Inc., San Diego, CA, USA. zhengyan.kan@pfizer.com., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Biostatistics, Pfizer Inc., San Diego, CA, USA., Real World Evidence, Pfizer Inc., New York, NY, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Global Biometrics & Data Management, Pfizer Inc., Cambridge, MA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA., Oncology Research & Development, Pfizer Inc., San Diego, CA, USA. Jadwiga.R.Bienkowska@pfizer.com.","zhengyan.kan@pfizer.com"
"39841349","Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.","2025 Jan 22","Kasai S","KONICA MINOLTA, INC, Tokyo, Japan.","satoshi-kasai@nuhw.ac.jp"
"39840660","One-year incidence of chemotherapy-induced peripheral neuropathy in oxaliplatin- or taxane-based chemotherapy: a multicenter, prospective registry study (MiroCIP study).","2025 Feb","Kodama S, Kuwabara S","ASCA Primary Product Department, ASCA Business Division, Daiichi Sankyo Co., Ltd., Chuo-ku, Tokyo, Japan., Data Intelligence Department, Global DX, Daiichi Sankyo Co., Ltd., Shinagawa-ku, Tokyo, Japan.","N/A"
"39840532","Peptide-Drug Conjugate for Therapeutic Reprogramming of Tumor-Associated Macrophages in Breast Cancer.","2025 Jan 22","Peranzoni E, Modesti L, Scodeller P","Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy., Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy., Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV - IRCCS, Padua, 35128, Italy.","N/A"
"39839709","Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact.","2025 Mar","N/A","Guardant Health, Inc., Redwood City, CA 94063, USA., Guardant Health, Inc., Redwood City, CA 94063, USA.","N/A"
"39838687","The Expression of the LDLR, LDLRAP1, and PCSK9 Genes has Prognostic Significance in Triple-negative Breast Cancer.","2025 Jan 20","Solopova ON","Research Institute of Experimental Diagnostics and Tumor Therapy, Blokhin National Medical Research Center of Oncology, Moscow, Russia.","N/A"
"39838193","A multicenter, randomized, open label, two formulation, crossover bioequivalence trial of doxorubicin hydrochloride liposomal injection in Chinese patients with metastatic breast cancer.","2025 Jan 22","Lv X","Shanghai Xihua Scientific Co., Ltd., Shanghai, China.","wujunyan@mail.sysu.edu.cn"
"39838118","Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial.","2025 Feb","Ungureanu A","Sarah Cannon Research Institute, Nashville, TN, USA.","sherene.loi@petermac.org"
"39838117","Pembrolizumab and chemotherapy in high-risk, early-stage, ER(+)/HER2(-) breast cancer: a randomized phase 3 trial.","2025 Feb","N/A","Merck & Co., Inc., Rahway, NJ, USA., Merck & Co., Inc., Rahway, NJ, USA., Merck & Co., Inc., Rahway, NJ, USA., Merck & Co., Inc., Rahway, NJ, USA.","fcardoso@abcglobalalliance.org"
"39837395","Synthesis, anti-proliferation, apoptosis induction in breast cancer cells, and aromatase inhibition of coumarin-triazole hybrids: In vitro and in silico studies.","2025 Mar","Ruchirawat S","Laboratory of Medicinal Chemistry, Chulabhorn Research Institute, Bangkok, 10210, Thailand; Program in Chemical Sciences, Chulabhorn Graduate Institute, Bangkok, 10210, Thailand; Center of Excellence on Environmental Health and Toxicology (EHT), Commission on Higher Education, Ministry of Education, Bangkok, 10400, Thailand.","veda.pra@mahidol.ac.th"
"39836421","External Validation of a 5-Factor Risk Model for Breast Cancer-Related Lymphedema.","2025 Jan 2","Shi W, Xu W, Kwan JYY","Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Research Institute, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.","N/A"
"39834054","Advanced glycation end products and breast cancer risk in a sample of the ORDET cohort.","2025 Jan 20","de Palma A, Sieri S","National Research Council of Italy, Clinical Proteomics Laboratory, Elixir Infrastructure, Institute Biomedical Technologies, ITB-CNR, Segrate, Milan, Italy., National Research Council of Italy, Clinical Proteomics Laboratory, Elixir Infrastructure, Institute Biomedical Technologies, ITB-CNR, Segrate, Milan, Italy.","N/A"
"39833133","Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production.","2025 Dec","Cheeseman J, Urbanowicz PA, Gardner RA, Spencer DIR","Ludger, Ltd., Culham Campus, Abingdon, Oxfordshire, UK., Ludger, Ltd., Culham Campus, Abingdon, Oxfordshire, UK., Ludger, Ltd., Culham Campus, Abingdon, Oxfordshire, UK., Ludger, Ltd., Culham Campus, Abingdon, Oxfordshire, UK.","N/A"
"39832051","Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.","2025 Jan 20","Honda S","Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA.","thomas.rohan@einsteinmed.edu"
"39830672","Antiproliferative and Pro-apoptotic Activities of Tournefortia mutabilis vent. Leaves on the Human Breast Adenocarcinoma Cell Line (MCF-7).","2024 Jan-Dec","Alonso Masso-Rojas F, Paez Arenas A","Translational Medicine Laboratory, UNAM-INC Unit, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico., Translational Medicine Laboratory, UNAM-INC Unit, National Institute of Cardiology Ignacio Chavez, Mexico City, Mexico.","N/A"
"39829682","Targeting ROR2 homooligomerization disrupts ROR2-dependent signaling and suppresses stem-like cell properties of human breast adenocarcinoma.","2025 Jan 17","Zhang H","Xenta Biomedical Science Co., Ltd, Guangzhou 510060, China.","N/A"
"39828992","Identifying Complex Scheduling Patterns Among Patients With Cancer With Transportation and Housing Needs: Feasibility Pilot Study.","2025 Jan 17","Fong A, Boxley C, Schubel L, Arem H","MedStar Health Research Institute, 3007 Tilden St, Washington, DC, 20008, United States, 1 202-244-9807., MedStar Health Research Institute, 3007 Tilden St, Washington, DC, 20008, United States, 1 202-244-9807., MedStar Health Research Institute, 3007 Tilden St, Washington, DC, 20008, United States, 1 202-244-9807., MedStar Health Research Institute, 3007 Tilden St, Washington, DC, 20008, United States, 1 202-244-9807.","N/A"
"39828527","Computer-Aided Design of Self-Assembled Nanoparticles to Enhance Cancer Chemoimmunotherapy via Dual-Modulation Strategy.","2025 Jan 19","N/A","Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264000, China.","N/A"
"39828065","ZNF703 promotes Triple-Negative breast cancer cell progression and in combination with STK11 predicts disease recurrence (ZS -TNBC Model).","2025 Mar 20","Mu X, Mu Q, Zhang X","ProphetsMed Research Lab, 's-Gravenhage 2565GN, the Netherlands; Laidengda (Shanghai) Medical Technology Development Co., Ltd., Shanghai 200025, China., Laidengda (Shanghai) Medical Technology Development Co., Ltd., Shanghai 200025, China., ProphetsMed Research Lab, 's-Gravenhage 2565GN, the Netherlands; Laidengda (Shanghai) Medical Technology Development Co., Ltd., Shanghai 200025, China. Electronic address: hee_rainday@foxmail.com.","hee_rainday@foxmail.com"
"39827470","Untargeted Swab Touch Spray-Mass Spectrometry Analysis with Machine Learning for On-Site Breast Surgical Margin Assessment.","2025 Feb 4","N/A","Leeuwenhoek Laboratories Co. Ltd., Taipei 10672, Taiwan.","N/A"
"39826800","Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay.","2025 Jan 16","Li X, Zhang Y","Cerca Biotech, GmbH, Berlin, Germany., Cerca Biotech, GmbH, Berlin, Germany.","emad.rakha@nottingham.ac.uk"
"39826620","Transporter Expressions as Part of Required Scaling Factor to Support In vitro In vivo Extrapolation for Blood-Brain Barrier Drug Permeability.","2025 Jan 16","Cheong J, Hogan J, De Bruyn T, Guo J, Hop CECA","Genentech Inc, South San Francisco, CA, USA., Merck & Co., Inc., Rahway, NJ, USA., Genentech Inc, South San Francisco, CA, USA., Merck & Co., Inc., Rahway, NJ, USA., Genentech Inc, South San Francisco, CA, USA.","zubida.al-majdoub@manchester.ac.uk"
"39826476","HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers.","2025 Feb","Braso-Maristany F, Galvan P, Parker JS","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Life Edit Therapeutics, Morrisville, USA.","Filipa_Lynce@dfci.harvard.edu"
"39826197","Efficacy, safety, and patient-reported outcomes across young to older age groups of patients with HR+/HER2- advanced breast cancer treated with ribociclib plus endocrine therapy in the randomized MONALEESA-2, -3, and -7 trials.","2025 Feb 25","Gao M","Novartis Pharma AG, Basel, Switzerland.","llhart@wakehealth.edu"
"39825152","Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.","2025 Jan 17","Takahashi S, Nguyen D, O'Malley DM","H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Sarah Cannon Research Institute, Nashville, TN, USA., Florida Cancer Specialists and Research Institute, West Palm Beach, FL, USA.","prpohlmann@mdanderson.org"
"39821032","RANK/RANKL Signaling Pathway in Breast Development and Cancer.","2025","N/A","Oncobell, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. egsuarez@idibell.cat.","egsuarez@idibell.cat"
"39820772","B cells enhance IL-1 beta driven invasiveness in triple negative breast cancer.","2025 Jan 16","Toney NJ, Frerichs L, Modarai SR, Ma A, Archinal H, Ajayi GO, Sims-Mourtada J","Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA., Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute Christiana Care Health Services, Inc., 4701 Ogletown Stanton Rd Suite 4300, Newark, DE, 19713, USA. jsimsmourtada@christianacare.org.","jsimsmourtada@christianacare.org"
"39820749","Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial.","2025 Jan 16","Zhang D, Li T","Genor Biopharma Co., Ltd, Beijing, China., Genor Biopharma Co., Ltd, Beijing, China.","bhxu@hotmail.com"
"39820660","2023 National Clinical Database Annual Report by the Japan Surgical Society.","2025 Mar","N/A","The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan.","yoshizumi.tomoharu.717@m.kyushu-u.ac.jp"
"39820652","Elacestrant in women with estrogen receptor-positive and HER2-negative early breast cancer: results from the preoperative window-of-opportunity ELIPSE trial.","2025 Jan 16","Vidal M, Munoz-Mateu M, Galvan P","Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Translational Genomics and Targeted Therapeutics in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain.","N/A"
"39820410","Telpegfilgrastim for chemotherapy-induced neutropenia in breast cancer: A multicenter, randomized, phase 3 study.","2025 Feb 20","Sun L","Xiamen Amoytop Biotech Co., LTD, Xiamen, Fujian 361000, China.","N/A"
"39817967","CD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: Targeting the tumour inside out.","2025 May","Reina G","Empa Swiss Federal Laboratories for Materials Science and Technology, Lerchenfeldstrasse 5, St. Gallen 9014, Switzerland. Electronic address: giacomo.reina@empa.ch.","g.grimaldi@bradford.ac.uk"
"39816377","Phytosomes Loaded with Mastoparan-M Represent a Novel Strategy for Breast Cancer Treatment.","2025","Lin J","Xiamen Research Institute of Food and Drug Quality Inspection, Xiamen, People's Republic of China.","N/A"
"39814714","Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer.","2025 Jan 15","N/A","Shandong Laboratory of Yantai Drug Discovery, Bohai rim Advanced Research Institute for Drug Discovery, Shandong, China. ypli@simm.ac.cn.","zhangpch1@shanghaitech.edu.cn"
"39814685","Response: reevaluating the promise: is primary tumor surgery really the key to survival or just a misinterpretation in de novo stage IV breast cancer?","2025 Feb","Zhang B","Clinical Medical Center, China Biotechnology Co. Ltd., Beijing, China.","N/A"
"39812586","Evaluating the Impact of Changes in Artificial Intelligence-derived Case Scores over Time on Digital Breast Tomosynthesis Screening Outcomes.","2025 Feb","Elahi A, Conant EF","Now with JLS Consulting, Jupiter, Fla., iCAD, Inc, Nashua, NH.","N/A"
"39812376","Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.","2025 Mar 4","Kogai H, Tsukamoto S, Koga M, Miyano M, Akagi T, Yamaguchi A, Nakazawa Y","Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan., Tsukuba Research Laboratory, Eisai Co., Ltd., Ibaraki, Japan.","N/A"
"39810843","Comorbidities And Reducing InEquitieS (CARES): Feasibility of self-monitoring and community health worker support in management of comorbidities among Black breast and prostate cancer patients.","2025 Feb","Schubel LC, Peeples M, Miller KE, Bangerter LR, Fong A, Gallagher C, Mandelblatt J","Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., WellDoc, Inc, Columbia, MD, USA., WellDoc, Inc, Columbia, MD, USA., Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA., Health Economics and Aging Research Institute, MedStar Health, Washington, DC, USA., Healthcare Delivery Research, MedStar Health Research Institute, Washington, DC, USA.","N/A"
"39810347","Quantitative Site-Specific Glycoproteomics Reveals Glyco-Signatures for Breast Cancer Diagnosis.","2025 Jan 14","Qiao L","Bioinformatics Solutions Inc., Waterloo, Ontario N2L3K8, Canada.","N/A"
"39810332","""We Don't Get Drugs Targeted for Us:"" Applying the Integrated Behavioral Model to Understand Why Black Women Chose to Participate in a Breast Cancer Clinical Trial.","2025 Jan 14","Adan D Jr","Chandy John Lab, Indiana Cancer Research Institute.","N/A"
"39809268","Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer.","2025 Jan 21","Sun Q, Guo J","National Key Laboratory of Lead Druggability Research (Shanghai Institute of Pharmaceutical Industry Co. Ltd., China State Institute of Pharmaceutical Industry Co. Ltd.), Shanghai 200040, China., National Key Laboratory of Lead Druggability Research (Shanghai Institute of Pharmaceutical Industry Co. Ltd., China State Institute of Pharmaceutical Industry Co. Ltd.), Shanghai 200040, China.","zhanglijun0407@shutcm.edu.cn"
"39809172","Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score.","2024 Nov 22","Lim MC, Park SY","Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea., Center for Gynecologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea.","N/A"
"39808751","Validation of Clinical Dynamic Contrast-Enhanced Magnetic Resonance Imaging Perfusion Modeling and Neoadjuvant Chemotherapy Response Prediction in Breast Cancer Using (18)FDG and (64)Cu-DOTA-Trastuzumab Positron Emission Tomography Studies.","2025 Jan","Whitman J, Adhikarla V, Peterson JR, Cole J","SimBioSys Inc, Chicago, IL., Division of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA., Division of Mathematical Oncology and Computational Systems Biology, Beckman Research Institute, City of Hope, Duarte, CA., SimBioSys Inc, Chicago, IL., SimBioSys Inc, Chicago, IL.","N/A"
"39808498","An activin receptor-like kinase 1-governed monocytic lineage shapes an immunosuppressive landscape in breast cancer metastases.","2025 Jan 14","Bocci M","P2 Biopharma Consulting, North Reading, Massachusetts, USA., IO Biotech ApS, Copenhagen, Denmark.","N/A"
"39808164","Insulin and insulin-like growth factor and risk of postmenopausal estrogen receptor-positive breast cancer: a case-cohort analysis.","2025 Jan 14","Dashti SG","Murdoch Children's Research Institute, Melbourne, Australia.","N/A"
"39807517","A co-registration method to validate in vivo optical coherence tomography in the breast surgical cavity.","2025 Jan 15","N/A","Australian Research Council Centre for Personalised Therapeutics Technologies, Melbourne, Australia.","N/A"
"39806129","Second-Line Treatment Options for Patients with Metastatic Triple-Negative Breast Cancer: A Review of the Clinical Evidence.","2025 Jan 13","Albanell J","Hospital del Mar Research Institute, Barcelona, Spain.","jgsaenz@salud.madrid.org"
"39805314","Long-acting, progestin-based contraceptives and risk of breast, gynecological, and other cancers.","2025 Jan 14","Spilsbury K","Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia.","N/A"
"39804726","Unveiling patterns in spatial transcriptomics data: a novel approach utilizing graph attention autoencoder and multiscale deep subspace clustering network.","2025 Jan 6","Tian G, Yang J","Geneis (Beijing) Co. Ltd., Beijing 100102, China., Geneis (Beijing) Co. Ltd., Beijing 100102, China.","N/A"
"39803593","Rare Cell Population Analysis in Early-Stage Breast Cancer Patients.","2025","Borwornpinyo S, Adireklarpwong L, Chirappapha P","Premise Biosystems Co., Ltd. Bangkok, Thailand., Premise Biosystems Co., Ltd. Bangkok, Thailand., Premise Biosystems Co., Ltd. Bangkok, Thailand.","N/A"
"39802535","A Real-World Evidence Primer for Advanced Practice Providers: Integrating P-Reality X Into Shared Decision-Making for People With HR+/HER2- Metastatic Breast Cancer.","2024 Jul 22","Ryan JC","Pfizer Inc., New York, NY.","N/A"
"39802327","MRPL24 drives breast cancer metastasis and stemness by targeting c-MYC, BRD4, and STAT3.","2025 Feb","Khan IU","Complete Genomics Biochemistry-1, Department US CG Biochem, MGI Tech Co., Ltd. Beishan Industrial Zone, Yantian District, Shenzhen, 518083 China. ROR: https://ror.org/02yrqby68","N/A"
"39802275","Treatment Considerations for Pyoderma Gangrenosum After Reduction Mammoplasty in an Unsuspecting Patient Demographic.","2025 Jan","Rivard SC","NH Skin Cancer Surgery, LLC, Derry, NH.","N/A"
"39801513","B cells enhance IL-1 beta driven invasiveness in triple-negative breast cancer.","2024 Dec 31","Toney NJ, Opdenaker LM, Frerichs L, Modarai SR, Ma A, Archinal H, Ajayi GO, Sims-Mourtada J","Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute., Helen F Graham Cancer Center, and Research Institute.","N/A"
"39801156","Phytochlorin-Based Sonosensitizers Combined with Free-Field Ultrasound for Immune-Sonodynamic Cancer Therapy.","2025 Feb","Su J, Wang C, Li Q","EEC Biotech Co., Ltd., Guangzhou, 510070, China., EEC Biotech Co., Ltd., Guangzhou, 510070, China., EEC Biotech Co., Ltd., Guangzhou, 510070, China.","N/A"
"39798264","Quality-adjusted time without symptoms or toxicity analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2- positive metastatic breast cancer patients based on secondary use of the DESTINY-Breast03 trial.","2025 Feb 25","Hamilton E","Sarah Cannon Research Institute, Nashville, United States.","nataliya.bogoeva@putassoc.com"
"39797701","FT538, iPSC-derived NK cells, enhance AML cell killing when combined with chemotherapy.","2025 Jan","Mahmood S, Wong L, Valamehr B","Fate Therapeutics, Inc., San Diego, California, USA., Fate Therapeutics, Inc., San Diego, California, USA., Fate Therapeutics, Inc., San Diego, California, USA.","N/A"
"39797229","Everolimus Through Plasmatic Concentrations in Cancer Patients: Prospective Longitudinal Observational Multicentric Study (DIANA-1 Project).","2024 Dec 30","Esteve A, Rey M","Medical Oncology Department, Institut Catala Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Spain., Medical Oncology Department, Institut Catala Oncologia (ICO), Badalona Applied Research Group in Oncology (B-ARGO), Germans Trias I Pujol Research Institute (IGTP), 08916 Badalona, Spain.","N/A"
"39796710","The Complexity and Significance of Fibroblast Growth Factor (FGF) Signaling for FGF-Targeted Cancer Therapies.","2024 Dec 30","Facey COB, Boman BM","Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA., Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA., Center for Translational Cancer Research, Helen F. Graham Cancer Center & Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA.","N/A"
"39796693","Role of NF2 Mutation in the Development of Eleven Different Cancers.","2024 Dec 29","Patel AJ","Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA., Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, TX 77030, USA.","N/A"
"39796106","The Significance of Aldehyde Dehydrogenase 1 in Cancers.","2024 Dec 30","Facey COB, Boman BM","Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA., Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA., Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, 4701 Ogletown-Stanton Road, Newark, DE 19713, USA.","N/A"
"39794360","Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer.","2025 Jan 10","Maulding ND, Zhou W, Metcalfe C, Stuart JM, Hafner M","gRED Computational Sciences, Genentech Inc, South San Francisco, CA, USA., Discovery Oncology, Genentech Inc, South San Francisco, CA, USA., Discovery Oncology, Genentech Inc, South San Francisco, CA, USA., Discovery Oncology, Genentech Inc, South San Francisco, CA, USA., Discovery Oncology, Genentech Inc, South San Francisco, CA, USA., gRED Computational Sciences, Genentech Inc, South San Francisco, CA, USA. hafner.marc@gene.com., Discovery Oncology, Genentech Inc, South San Francisco, CA, USA. hafner.marc@gene.com.","hafner.marc@gene.com"
"39793692","Clinical impact of PTEN rs701848 as a predictive marker for breast cancer.","2025 Jan 8","El-Sayed AF","Molecular Genetics Department, Biotechnology Research Institute, National Research Centre, Giza, Egypt; Egypt Center for Research and Regenerative Medicine (ECRRM), Cairo, Egypt.","rmhaemd@hotmail.com"
"39792663","Noncanonical UPR factor CREB3L2 drives immune evasion of triple-negative breast cancer through Hedgehog pathway modulation in T cells.","2025 Jan 10","Li Z","K2 Oncology Co., Ltd., Beijing, China.","N/A"
"39789975","Design, Synthesis, and Pharmacodynamic Evaluation of Highly Selective PARP1 Inhibitors with Brain Penetrance.","2025 Jan 23","Wang T, Jia T","Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China., Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China., Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China.","N/A"
"39789619","A phase Ia study of a novel anti-HER2 antibody-drug conjugate GQ1001 in patients with previously treated HER2 positive advanced solid tumors.","2025 Jan 9","Sun Y","GeneQuantum Healthcare (Suzhou) Co.,Ltd., Suzhou, China.","liujieqiong01@163.com"
"39787991","Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while protecting normal cells.","2025 Mar","Zhang WY","FlynewBio.Inc, Irvine, CA 92617, USA.","yongwu@ucla.edu"
"39787453","Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.","2025 Jan 9","Hasegawa H, Uchida Y","Medical HQs, Eisai Co, Ltd, Tokyo, Japan., Medical HQs, Eisai Co, Ltd, Tokyo, Japan.","N/A"
"39786500","Traditional versus modern approaches to screening mammography: a comparison of computer-assisted detection for synthetic 2D mammography versus an artificial intelligence algorithm for digital breast tomosynthesis.","2025 Jan 9","Kshirsagar A, Pohlman S","Hologic, Inc., 250 Campus Drive, Marlborough, MA, 01752, USA., Hologic, Inc., 250 Campus Drive, Marlborough, MA, 01752, USA.","mbahl1@mgh.harvard.edu"
"39786405","Breast Cancer Susceptibility Gene Sequence Variations and Development of Contralateral Breast Cancer.","2024 Dec 2","Liang X","Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada.","N/A"
"39786401","OBI-992, a Novel TROP2-Targeted Antibody-Drug Conjugate, Demonstrates Antitumor Activity in Multiple Cancer Models.","2025 Feb 4","Li WF, Chiang MF, Weng HC, Yang JJ, Wu HS, Wu SY, Chen YJ, Lu CH, Tu JS, Hsu RY, Shia CS, Huang TY, Lai MT","OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan., OBI Pharma, Inc., Taipei, Taiwan.","N/A"
"39785866","Ultrasensitive Detection and Monitoring of Circulating Tumor DNA using Structural Variants in Early-Stage Breast Cancer.","2025 Jan 9","Alcaide M, Oton L","SAGA Diagnostics AB, Lund, Sweden., SAGA Diagnostics AB, Lund, Sweden.","N/A"
"39780231","Pharmacological Vitamin C-induced high H(2)O(2) generation mediates apoptotic cell death by caspase 3/7 activation in breast cancer tumor spheroids.","2025 Jan 8","N/A","Advanced Materials and Nanobiotechnology Laboratory, TardigradeNano LLC, Irvine, CA, 92604, USA.","rohimahm@usm.my"
"39780207","Exploring the role of splicing in TP53 variant pathogenicity through predictions and minigene assays.","2025 Jan 8","Fortuno C, Canson DM, Caldes S","Population Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia., Population Health Program, QIMR Berghofer Medical Research Institute, Herston, QLD, 4006, Australia. Amanda.Spurdle@qimrberghofer.edu.au.","Amanda.Spurdle@qimrberghofer.edu.au"
"39779897","Lymphatic collection and cell isolation from mouse models for multiomic profiling.","2025 Jan 8","Thangaswamy S","Legend Biotech, Somerset, NJ, USA.","jubellacker@hsph.harvard.edu"
"39779563","A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.","2025 Jan 6","Rahmanian M","Biomaterials and Tissue Engineering Research Group, Interdisciplinary Technologies Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.","N/A"
"39779447","Efficacy outcomes of CDK4/6 inhibitors in combination with endocrine therapy treatment in hormone receptor-positive/HER2-negative advanced breast cancer according to PAM50 intrinsic subtype: Primary results of SOLTI-1801 CDK-PREDICT study.","2025 Feb 25","Martinez-Saez O, Braso-Maristany F, Garcia-Fructuoso I, Rodriguez A","Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain.","Pablo.tolosa@salud.madrid.org"
"39778071","Frequency of Missing TNM Stage Data for Adults With Intellectual or Developmental Disabilities in a Provincial Cancer Registry-A Brief Report.","2025 Jan","Brownell M, Turner D","Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Manitoba, Canada., Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Manitoba, Canada., Paul Albrechtsen Research Institute, CancerCare Manitoba, Winnipeg, Manitoba, Canada.","N/A"
"39777588","Minimal residue disease detection in early-stage breast cancer: a review.","2025 Jan 7","Yuan X","Shuwen Biotech Co., Ltd., Moganshan National High tech Zone, Building 3, No. 333, Changhong Middle Street, Deqing, China., Shuwen Biotech Co., Ltd., Moganshan National High tech Zone, Building 3, No. 333, Changhong Middle Street, Deqing, China. yuanxy@shuwendx.com.","yuanxy@shuwendx.com"
"39776810","Perfluorocarbon-polyepinephrine core-shell nanoparticles as a near-infrared light activatable theranostic platform for bimodal imaging-guided photothermal/chemodynamic synergistic cancer therapy.","2025","Lee KK, Park KW, Lee CS","Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea., Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea., Bionanotechnology Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Republic of Korea.","N/A"
"39776341","Therapeutic Efficacy Studies on the Monoterpenoid Hinokitiol in the Treatment of Different Types of Cancer.","2025 Jan 7","Chowdhury R, Akbor MS, de Alencar MVOB, Islam MT","Phytochemistry and Biodiversity Research Laboratory, BioLuster Research Center Ltd, Gopalganj, Dhaka, Bangladesh., Phytochemistry and Biodiversity Research Laboratory, BioLuster Research Center Ltd, Gopalganj, Dhaka, Bangladesh., Phytochemistry and Biodiversity Research Laboratory, BioLuster Research Center Ltd, Gopalganj, Dhaka, Bangladesh., Phytochemistry and Biodiversity Research Laboratory, BioLuster Research Center Ltd, Gopalganj, Dhaka, Bangladesh., Phytochemistry and Biodiversity Research Laboratory, BioLuster Research Center Ltd, Gopalganj, Dhaka, Bangladesh.","N/A"
"39776332","Photodynamic therapy as a strategic ally in radiotherapy for triple-negative breast cancer: the importance of treatment order.","2025 Jan 8","Silva CR, Vieira DP, de Freitas AZ, Ribeiro MS","Center for Lasers and Applications, Energy and Nuclear Research Institute (IPEN-CNEN), Av. Lineu Prestes, 2242, Sao Paulo, Brazil., Center of Biotechnology, Energy and Nuclear Research Institute (IPEN-CNEN), Av. Lineu Prestes, 2242, Sao Paulo, Brazil., Center for Lasers and Applications, Energy and Nuclear Research Institute (IPEN-CNEN), Av. Lineu Prestes, 2242, Sao Paulo, Brazil., Center for Lasers and Applications, Energy and Nuclear Research Institute (IPEN-CNEN), Av. Lineu Prestes, 2242, Sao Paulo, Brazil. marthasr@usp.br.","marthasr@usp.br"
"39776103","The impact of tamoxifen on apolipoproteins and lipoprotein(a) levels: an updated meta-analysis of randomized controlled trials.","2025 Jan 7","Zhang L","Shanghai Henlius Biopharmaceutical Co, Ltd, Shanghai, 200233, China.","saya8891@hotmail.com"
"39775325","Generation of deep learning based virtual non-contrast CT using dual-layer dual-energy CT and its application to planning CT for radiotherapy.","2024","N/A","Division of Biomedical Metrology, Ionizing Radiation Group, Korea Research Institute of Standards and Science, Daejeon, Republic of Korea.","N/A"
"39774938","Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum.","2024 Nov 1","Coler R, Berube BJ","Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA., Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle, WA.","N/A"
"39774684","Adjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).","2025 Jan 7","Kalashnikova E, Rodriguez A, Liu MC, Aleshin A","Natera Inc., Austin, TX, USA., Natera Inc., Austin, TX, USA., Natera Inc., Austin, TX, USA., Natera Inc., Austin, TX, USA.","abardia@mednet.ucla.edu"
"39774360","Sentinel lymph nodes biopsy for malignant tumors using Technefit radioactive colloid Technetium (99m)Tc.","2024 Dec 31","Onofriychuk I, Zikiryahodzhaev A, Ermakov A, Ablitsova N, Saribekyan E, Rasskazova E, Mikhailov S","Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia., Moscow Research Institute of Oncology n.a. P.A. Herzen - Branch of the National Medical Research Centre of Radiology, Moscow, Russia.","N/A"
"39773237","Correction: c-MET-positive circulating tumor cells and cell-free DNA as independent prognostic factors in hormone receptor-positive/HER2-negative metastatic breast cancer.","2025 Jan 7","Sung M, Lee H, Kang MR, Shin YK","Technical Research Center, Genobio Corp., Seoul, Republic of Korea., R&D Center, ABION Inc., Seoul, Republic of Korea., R&D Center, ABION Inc., Seoul, Republic of Korea., R&D Center, Gencurix Inc., Seoul, Republic of Korea., R&D Center, ABION Inc., Seoul, Republic of Korea. ykeeshin@snu.ac.kr.","ykeeshin@snu.ac.kr"
"39769460","Microbubble-Protected Oncolytic Virotherapy Targeted by Sonoporation Induces Tumor Necrosis and T-Lymphocyte Infiltration in Humanized Mice Bearing Triple-Negative Breast Cancer.","2024 Dec 21","Schutt EG, Li R, Howard CM","Vesselon, Inc., Norwalk, CT 06851, USA., Vesselon, Inc., Norwalk, CT 06851, USA., Vesselon, Inc., Norwalk, CT 06851, USA.","N/A"
"39769454","The Complex Role of Matrix Metalloproteinase-2 (MMP-2) in Health and Disease.","2024 Dec 21","N/A","Thrombosis and Hemostasis Program, VERSITI Blood Research Institute, Milwaukee, WI 53226, USA.","N/A"
"39769441","Dysregulated miRNA Expression and Androgen Receptor Loss in Racially Distinct Triple-Negative Breast Cancer.","2024 Dec 21","Nunes-Souza E, Fonseca AS, Chandrashekar DS, Aneja R","Research Institute Pele Pequeno Principe, Faculdades Pequeno Principe, Curitiba 80250-060, PR, Brazil., Research Institute Pele Pequeno Principe, Faculdades Pequeno Principe, Curitiba 80250-060, PR, Brazil., Research Institute Pele Pequeno Principe, Faculdades Pequeno Principe, Curitiba 80250-060, PR, Brazil., Research Institute Pele Pequeno Principe, Faculdades Pequeno Principe, Curitiba 80250-060, PR, Brazil.","N/A"
"39769392","Use of Gain-of-Function Screening to Identify miRNAs Involved in Paclitaxel Resistance in Triple-Negative Breast Cancer.","2024 Dec 20","Nemours S, Sole C, Armesto M, Arestin M, Urruticoechea A, Schaapveld R, Zhang L, Lawrie CH","Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., Breast Cancer Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., Breast Cancer Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain., InteRNA Technologies, 3584 Utrecht, The Netherlands., InteRNA Technologies, 3584 Utrecht, The Netherlands., Molecular Oncology Group, Biogipuzkoa Health Research Institute, 20014 San Sebastian, Spain.","N/A"
"39769279","Latest Therapeutical Approaches for Triple-Negative Breast Cancer: From Preclinical to Clinical Research.","2024 Dec 17","Pont M, Sorolla A","Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain., Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain., Research Group of Cancer Biomarkers, Biomedical Research Institute of Lleida (IRBLleida), Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain.","N/A"
"39768151","ALDH(High) Breast Cancer Stem Cells Exhibit a Mesenchymal-Senescent Hybrid Phenotype, with Elevated Metabolic and Migratory Activities.","2024 Dec 13","Moftakhar Z, Sotgia F","Lunella Biotech, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada., Lunella Biotech, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada., Lunella Biotech, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada., Lunella Biotech, 1145 Carling Avenue, Ottawa, ON K1Z 7K4, Canada.","N/A"
"39767574","RELT Is Upregulated in Breast Cancer and Induces Death in Breast Cancer Cells.","2024 Nov 22","Mohamed E","California Pacific Medical Center Research Institute, San Francisco, CA 94107, USA.","N/A"
"39767212","Comparison of Vendor-Pretrained and Custom-Trained Deep Learning Segmentation Models for Head-and-Neck, Breast, and Prostate Cancers.","2024 Dec 18","N/A","RaySearch Laboratories AB, 113 68 Stockholm, Sweden.","N/A"
"39766811","Loss of Heterozygosity (LOH) Affecting HLA Genes in Breast Cancer: Clinical Relevance and Therapeutic Opportunities.","2024 Nov 28","Ronco-Diaz V","Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain., Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain., Biosanitary Research Institute of Granada (ibs.GRANADA), 18012 Granada, Spain.","N/A"
"39766305","Characterization of Loss-of-Imprinting in Breast Cancer at the Cellular Level by Integrating Single-Cell Full-Length Transcriptome with Bulk RNA-Seq Data.","2024 Dec 14","Coussement L","Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium., Cancer Research Institute Ghent (CRIG), 9000 Ghent, Belgium.","N/A"
"39766103","Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer.","2024 Dec 17","Nakamura M","Cancer Precision Medicine Inc., Kawasaki 213-0012, Japan.","N/A"
"39765189","Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.","2025 Jan","Rubio-Perez C, Segui E, Conte B, Albarran-Fernandez V, Aguirre A, Galvan P, Cobo S, Rey M, Martinez-Romero A, Walbaum B, Schettini F, Vidal M, Munoz M, Adamo B, Guedan S, Grzelak M, Borcherding N, Heyn H, Braso-Maristany F","Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain., Cellular Immunotherapies for Cancer Group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain., Omniscope Inc., Palo Alto, USA., Omniscope Inc., Palo Alto, USA., Omniscope Inc., Palo Alto, USA., Translational Genomics and Targeted Therapies in Solid Tumors group, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Institute of Cancer and Blood Diseases, Hospital Clinic of Barcelona, Barcelona, Spain; Reveal Genomics, Barcelona, Spain. Electronic address: FBRASO@recerca.clinic.cat.","FBRASO@recerca.clinic.cat"
"39764461","Medication non-adherence: reflecting on two decades since WHO adherence report and setting goals for the next twenty years.","2024","Unni E","Syreon Research Institute, Budapest, Hungary., Syreon Research Institute, Budapest, Hungary.","N/A"
"39763667","Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.","2024","St Hilare I, Bell JC, Melcher AA, Ilkow C","Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada., Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada., The Institute of Cancer Research, Divisions of Radiotherapy and Imaging and Breast Cancer Research, Chester Beatty Laboratories, London, United Kingdom., Center for Innovative Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.","N/A"
"39763064","Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.","2025 Jan","Coleborn E","Queensland Cyber Infrastructure Foundation Ltd (QCIF), Facility for Advanced Bioinformatics, St Lucia, Queensland, Australia.","N/A"
"39762945","Serum metabolomic profiling for predicting therapeutic response and toxicity in breast cancer neoadjuvant chemotherapy: a retrospective longitudinal study.","2025 Jan 6","N/A","Analytical Instrument Trading Co., Ltd, SCIEX, Shanghai, China.","cheng_guo@zju.edu.cn"
"39762422","Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.","2025 Jan","Gordon M, Yachnin J, Galvao V, Schiza A, Laurie SA, Mancuso MR, Muller L, Fine GD, Yadav M, Leveque VJP, Robert A, Darwish M, Qi T, Zhu J, Zhang J, Twomey P, Rao GK, Low DW, Petry C, Lo AA, Schartner JM, Delamarre L, Mellman I, Lower M, Muller F, Derhovanessian E, Cortini A, Manning L","The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA., HonorHealth Research Institute, Scottsdale, AZ, USA., Sarah Cannon Research Institute, Nashville, TN, USA., Seagen, Inc., Bothell, WA, USA., Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA. mancuso.michael@gene.com., Genentech, Inc., South San Francisco, CA, USA., Stork Therapeutics, San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Bluejay Therapeutics, San Mateo, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Artera, Inc., Los Altos, CA, USA., Genentech, Inc., South San Francisco, CA, USA., AbbVie, Inc., Santa Clara, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA., Genentech, Inc., South San Francisco, CA, USA.","juanita.lopez@icr.ac.uk"
"39762287","Selectively expressed RNA molecules as a versatile tool for functionalized cell targeting.","2025 Jan 6","Hoffmann B","SRTD biotech GmbH, Juelich, Germany.","b.hoffmann@fz-juelich.de"
"39761672","Assessing the Impact of Multidisciplinary Cancer Consultations on Cancer Quality Metrics.","2024 Dec 1","Zeruto C","Information Management Services, Inc, Calverton, Calverton.","N/A"
"39760980","Comparing loss of contractual employment pre- and post-diagnosis in patients with rare versus common cancer types: a national registry-based study.","2025 Jan 6","Motazedi E, Coenen P","Societal Participation and Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands., Societal Participation and Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands., Societal Participation and Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands., Musculoskeletal Health, Amsterdam Movement Sciences Research Institute, Amsterdam, The Netherlands., Societal Participation and Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands., Societal Participation and Health, Amsterdam Public Health Research Institute, Amsterdam, The Netherlands. s.duijts@iknl.nl.","s.duijts@iknl.nl"
"39760460","Rhus Verniciflua Stokes Inhibits PD-1 Expression and Induces Anticancer Effects by Enhancing T Cell Function.","2025 Jan-Dec","Kim S, Lee YK","Eutilex Co. Ltd., Geumcheon-gu, Seoul, Republic of Korea., Excelsisbio Inc., Goyang-si, Gyeonggi-do, Republic of Korea.","N/A"
"39760151","Antibody/siRNA Nanocarriers Against Wnt Signaling Suppress Oncogenic and Stem-Like Behavior in Triple-Negative Breast Cancer Cells.","2025 Jan","N/A","Cawley Center for Translational Cancer Research, Helen F. Graham Cancer Center and Research Institute, Newark, Delaware, USA.","N/A"
"39757921","HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.","2025 Jan 6","N/A","Global Oncology Medical Affairs, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Research and Development, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA., Research and Development, Daiichi Sankyo Inc., Basking Ridge, New Jersey, USA.","N/A"
"39757146","Single cell and spatial analysis of immune-hot and immune-cold tumours identifies fibroblast subtypes associated with distinct immunological niches and positive immunotherapy response.","2025 Jan 6","King EV, Bates JG, Hanley CJ, Thomas GJ","Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US., Gilead Sciences Inc., Foster City, CA, US.","g.thomas@soton.ac.uk"
"39755825","Historical redlining and clustering of present-day breast cancer factors.","2025 Jan 4","Aldstadt J","Policy Research Solutions LLC (PRESTO), Buffalo, NY, USA.","sarahlim@buffalo.edu"
"39754979","Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting.","2025 Jan","Liu X, Li B, McRoy L, Estevez M","Pfizer Inc., New York, USA., Pfizer Inc., New York, USA., Pfizer Inc., New York, USA., Flatiron Health Inc., New York, USA.","hope.rugo@ucsf.edu"
"39753771","Refining breast cancer genetic risk and biology through multi-ancestry fine-mapping analyses of 192 risk regions.","2025 Jan","Nemesure B, Olshan AF","Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan., Division of Cancer Information and Control, Aichi Cancer Center Research Institute, Nagoya, Japan.","wei.zheng@vanderbilt.edu"
"39753653","The optimal neoadjuvant treatment strategy for HR+/HER2 + breast cancer: a network meta-analysis.","2025 Jan 3","Yu X, Mi K, Wang H","Shanghai Roche Pharmaceuticals Ltd, Shanghai, China., Shanghai Roche Pharmaceuticals Ltd, Shanghai, China., Shanghai Roche Pharmaceuticals Ltd, Shanghai, China.","mikun@uestc.edu.cn"
"39751965","FcRn-guided antigen trafficking enhances cancer vaccine efficacy.","2025 Jan 3","Liu G, Han T, Fei C, Wu S, Ma H","Therarna. Co. Ltd., Nanjing, 210000, Jiangsu, China., Therarna. Co. Ltd., Nanjing, 210000, Jiangsu, China., Therarna. Co. Ltd., Nanjing, 210000, Jiangsu, China., Anhui Genebiol Biotech. LTD., Hefei, 230000, China., Anhui Genebiol Biotech. LTD., Hefei, 230000, China., Therarna. Co. Ltd., Nanjing, 210000, Jiangsu, China. xushi@therarna.cn., Anhui Genebiol Biotech. LTD., Hefei, 230000, China. jint@ustc.edu.cn.","zhoushoubingseu@126.com"
"39751931","Therapeutic potential of anti-ErbB3 chimeric antigen receptor natural killer cells against breast cancer.","2025 Jan 3","Yoo W, Choi H, Lee S, Kim TD","Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea., Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, 34141, Republic of Korea., Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea., Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea. tdkim@kribb.re.kr.","jangjune.park@isu.co.kr"
"39749685","Multiscale 3D spatial analysis of the tumor microenvironment using whole-tissue digital histopathology.","2025 Jan 3","Xu Z","Advanced Cellular and Tissue Microscope Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas, USA., Advanced Cellular and Tissue Microscope Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas, USA., Advanced Cellular and Tissue Microscope Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas, USA., Advanced Cellular and Tissue Microscope Shared Resource, Houston Methodist Research Institute and Houston Methodist Neal Cancer Center, Houston, Texas, USA.","N/A"
"39747865","The spatially informed mFISHseq assay resolves biomarker discordance and predicts treatment response in breast cancer.","2025 Jan 2","Huraiova B, Matyasovska N, Gubova S, Ondris T, Bendikova S, Buranovska K, Krchnakova Z, Lovisek D, Mancikova V, Ristova M, Andrasina I, Tuschl T, Kather JN","MultiplexDX, Inc, Rockville, MD, USA. paul@multiplexdx.com., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA., MultiplexDX, Inc, Rockville, MD, USA. pavol@multiplexdx.com.","paul@multiplexdx.com"
"39746964","Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after >/= 2 prior lines of chemotherapy: a phase Ib study.","2025 Jan 2","Liu Y, Niu M, Zhao X","CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, China., CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, China., CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd, Shijiazhuang, China.","xubinghe@medmail.com.cn"
"39746162","Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer.","2025 Jan 2","Ligibel J","Natera, Inc, San Carlos, CA.","N/A"
"39745368","TOP1 Mutations and Cross-Resistance to Antibody-Drug Conjugates in Patients with Metastatic Breast Cancer.","2025 Jan 2","Weipert C","Guardant Health, Inc., Redwood City, CA, United States.","N/A"
"39744000","Unlocking the epigenetic code: new insights into triple-negative breast cancer.","2024","Romero-Moreno R","Harper Cancer Research Institute, South Bend, IN, United States.","N/A"
"39743589","Aspartate signalling drives lung metastasis via alternative translation.","2025 Feb","N/A","WELBIO Department, WEL Research Institute, Wavre, Belgium.","sarah-maria.fendt@kuleuven.be"
"39742559","Predicting benefit from PARP inhibitors using deep learning on H&E-stained ovarian cancer slides.","2025 Feb 5","Krieghoff-Henning EI, Kiehl L, Brinker TJ","Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), Heidelberg, Germany., Division of Digital Prevention, Diagnostics and Therapy Guidance, German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: titus.brinker@dkfz.de.","titus.brinker@dkfz.de"
"39742359","Digital Self-Management Intervention Paths for Early Breast Cancer Patients: Results of a Pilot Study.","2024","Kolokotroni E","Foundation for Research and Technology-Hellas Biomedical Research Institute, Ionnina, Greece.","N/A"
"39742310","iMeta Conference 2024: Building an innovative scientific research ecosystem for microbiome and One Health.","2024 Dec","Chang L, Chen D, Cheng C, He R, Xuemeng L, Liang L, Liu L, Ma XY, Xia X, Xiao Y, Xue H, Zhang FL, Lei L, Shi H, Sun HZ, Liu SJ, Yin Y, Liu YX","Guangdong Magigene Biotechnology Co., Ltd. China., NovelBio Bio-Pharm Technology Co., Ltd. Shanghai China., Shenzhen Wedge Microbiology Research Co., Ltd. Shenzhen China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China., AxbioBiotechnology (Shenzhen) Co., Ltd. Shenzhen China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China., Chi-Biotech Co. Ltd. Shenzhen China., Chi-Biotech Co. Ltd. Shenzhen China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China., NovelBio Bio-Pharm Technology Co., Ltd. Shanghai China., Xiamen Chengge Biotechnology Co., Ltd Xiamen China., GigaScience Press, BGI Shenzhen Co. Ltd., BGI Center Shenzhen China., John Wiley & Sons, Inc. Beijing China., R-Institute Co. Ltd. Beijing China., R-Institute Co. Ltd. Beijing China., Xiamen Treatgut Biotechnology Co., Ltd Xiamen China.","N/A"
"39741404","Controlling intracellular protein delivery, tumor colonization and tissue distribution using flhDC in clinically relevant DeltasseJ Salmonella.","2025 Feb 5","Wetherby VE, Van Dessel N","Ernest Pharmaceuticals, Inc., Hadley, MA 01035, USA., Ernest Pharmaceuticals, Inc., Hadley, MA 01035, USA.","forbes@umass.edu"
"39740986","Socioeconomic inequalities in adherence to clinical practice guidelines and breast cancer survival: a multicentre population-based study in Spain.","2024 Dec 31","Sanchez MJ","Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology (ICO). Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Spain., Josep Carreras Leukemia Research Institute, Girona, Spain., Epidemiology Unit and Girona Cancer Registry, Oncology Coordination Plan, Catalan Institute of Oncology (ICO). Girona Biomedical Research Institute (IDIBGI-CERCA), Girona, Spain.","daniel.redondo.easp@juntadeandalucia.es"
"39740913","The Relationship of Metabolic Activity and alphavbeta3 Receptor Expression in Aggressive Breast Cancer Subtypes Tumors: A Preliminary Report.","2025 Jan-Feb","Csikos C, Denes N","Scanomed Ltd., Debrecen, Hungary., Scanomed Ltd., Debrecen, Hungary., Scanomed Ltd., Debrecen, Hungary.","ngo@mailbox.unideb.hu"
"39740910","In Vivo Antitumor Activity of the PD-1/PD-L1 Inhibitor SCL-1 in Various Mouse Tumor Models.","2025 Jan-Feb","Ashizawa T, Iizuka A, Kanematsu A, Maeda C, Miyata H, Yamashita K, Ikeya T, Kikuchi Y, Maruyama K, Urakami K, Yamaguchi K","Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Experimental Animal Facility, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Cancer Diagnostic Research Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan., Immunotherapy Division, Shizuoka Cancer Center Research Institute, Shizuoka, Japan; y.akiyama@scchr.jp.","y.akiyama@scchr.jp"
"39740820","Eribulin Induction of Immunogenic Cell Death (ICD): Comparison With Other Cytotoxic Agents and Temporal Relationship of ICD Biomarkers.","2025 Jan","Zang M, Zheng J, An X, Li BO, Yang H, Littlefield BA","Crown Bioscience Inc., Taicang, P.R. China., Crown Bioscience Inc., Taicang, P.R. China., Crown Bioscience Inc., Taicang, P.R. China., Crown Bioscience Inc., Taicang, P.R. China., Crown Bioscience Inc., Taicang, P.R. China., Eisai Inc., Cambridge, MA, U.S.A. bruce_littlefield@eisai.com.","bruce_littlefield@eisai.com"
"39738367","Tumor hypoxia evidences the differential regulation of Mdm2-p53 axis by PTEN in tumor derived vs. normal endothelial cells.","2024 Dec 30","Wilkus-Adamczyk K, Kieda C","Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine- National Research Institute, PL-04-141, Warsaw, Poland. wilkuskinga@gmail.com., Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine- National Research Institute, PL-04-141, Warsaw, Poland. kbrodaczewska@wim.mil.pl., Laboratory of Molecular Oncology and Innovative Therapies, Military Institute of Medicine- National Research Institute, PL-04-141, Warsaw, Poland.","wilkuskinga@gmail.com"
"39737957","NOS inhibition sensitizes metaplastic breast cancer to PI3K inhibition and taxane therapy via c-JUN repression.","2024 Dec 30","Puri A, Thomas C, Zhou J, Zhao H, Oo A, Cho YJ, Kim B, Giese N, Wink D, Lockett S, Wong S, Krishnamurthy S, Meric-Bernstam F","Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA., Houston Methodist Research Institute, Houston, TX, USA. jcchang@houstonmethodist.org.","jcchang@houstonmethodist.org"
"39737515","Management of T cell responses by anesthetic drugs-propofol & isoflurane in perioperative breast cancer patients: A prospective hospital-based study.","2024 Nov","Kumar S","Division of Agricultural Bioinformatics, Indian Agricultural Statistics Research Institute, New Delhi, India.","N/A"
"39736699","Unraveling the protein kinase C/NDRG1 signaling network in breast cancer.","2024 Dec 30","De Summa S, Traversa D, Pirini F","Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori ""Giovanni Paolo II"", 70124, Bari, Italy., Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori ""Giovanni Paolo II"", 70124, Bari, Italy., Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) ""Dino Amadori"", Meldola, Italy.","marco.trerotola@unich.it"
"39735986","Differential Response to Cisplatin between Co-cultured Cells and Pure Cultured Cells Based on Single-cell RNA Sequencing of Three-dimensional-cultured Breast Cancer Cells.","2024 Nov 29","Lin K, Li W, Ye G","Clinical Research Institute, The First People's Hospital of Foshan, 528100 Foshan, Guangdong, China., Clinical Research Institute, The First People's Hospital of Foshan, 528100 Foshan, Guangdong, China., Clinical Research Institute, The First People's Hospital of Foshan, 528100 Foshan, Guangdong, China.","N/A"
"39734228","Polygenic score distribution differences across European ancestry populations: implications for breast cancer risk prediction.","2024 Dec 29","Andrulis IL, Arndt V, Brantley KD, Eccles DM, Michailidou K","Fred A, Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada., NN Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus., NN Alexandrov Research Institute of Oncology and Medical Radiology, Minsk, Belarus., Cancer Research Program, QIMR Berghofer Medical Research Institute, Brisbane, QLD, Australia., Genome Diagnostics Program, IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy.","kyriakimi@cing.ac.cy"
"39732735","Comprehensive Mass Spectral Libraries of Human Thyroid Tissues and Cells.","2024 Dec 28","Guan H","Westlake Omics (Hangzhou) Biotechnology Co., Ltd., No. 1 Yunmeng Road, Hangzhou, 310024, China.","wangyingrui@westlake.edu.cn"
"39732565","Dabrafenib upregulates hypoglycosylated MUC1 and improves the therapeutic efficacy of Tn-MUC1 CAR-T cells.","2024 Dec 3","Zhou C, Lin Y, An H, Yin H","Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou 510535, China., Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou 510535, China., Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou 510535, China., Guangzhou Anjie Biomedical Technology Co. Ltd, Guangzhou 510535, China. Electronic address: hmikeyin@hotmail.com.","hmikeyin@hotmail.com"
"39732367","Prognostic Impact of Tumor Cell Nuclear Size Assessed by Artificial Intelligence in Esophageal Squamous Cell Carcinoma.","2024 Dec 26","Nearchou IP","Indica Labs Inc., Albuquerque, New Mexico.","tsujihi@ndmc.ac.jp"
"39731080","Gene expression profiling for the diagnosis of male breast cancer.","2024 Dec 27","Qi P, Pang Y, Xu M","Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd, Hangzhou, China., Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd, Hangzhou, China., Canhelp Genomics Research Center, Canhelp Genomics Co., Ltd, Hangzhou, China.","xumd@shca.org.cn"
"39730856","Empowerment among breast cancer survivors using an online peer support community.","2024 Dec 28","Ruiz-Romeo M, Serra-Blasco M, Flix-Valle A, Villanueva-Bueno C, Juan-Linares E","The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain., The Bellvitge Biomedical Research Institute IDIBELL, Psychooncology and Digital Health Group, Hospitalet de Llobregat, Spain. cochoa@iconcologia.net.","cochoa@iconcologia.net"
"39730439","Accuracy of breast ultrasound image analysis software in feature analysis: a comparative study with sonographers.","2024 Dec 28","Wang Y","Project Department, Tend.AI Medical Technologies Co., Ltd, Shanghai, China.","hufan@sjtu.edu.cn"
"39730333","Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption.","2024 Dec 27","Beckers C, Da Silva Morais M, Sonveaux P","Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), UCLouvain, Brussels, Belgium., Nuclear and Electron Spin Technologies (NEST) Platform, LDRI, UCLouvain, Brussels, Belgium., Biomedical Magnetic Resonance Research Group, Louvain Drug Research Institute (LDRI), UCLouvain, Brussels, Belgium., WEL Research Institute, WELBIO Department, Wavre, Belgium. pierre.sonveaux@uclouvain.be.","pierre.sonveaux@uclouvain.be"
"39730175","Immune Stress-induced Tumor Mutation Burden and Neoantigen Expression in 4T1 Mammary Cancer Cells: A Potential Mechanism for Long-term Survival in Patients Treated With Immune Checkpoint Inhibitors.","2025 Jan-Feb","N/A","AntiCancer Inc., San Diego, CA, U.S.A.","ttsunoda@med.showa-u.ac.jp"
"39729623","Multi-angle acquisition and 3D composite reconstruction for organ-targeted PET using planar detectors.","2024 Dec 27","Anashkin E, Komarov B, Baldassi B, Babich A, Reznik A","Radialis Inc., Thunder Bay, Ontario, Canada., Radialis Inc., Thunder Bay, Ontario, Canada., Radialis Inc., Thunder Bay, Ontario, Canada., Radialis Inc., Thunder Bay, Ontario, Canada., Radialis Inc., Thunder Bay, Ontario, Canada., Thunder Bay Regional Health Research Institute, Thunder Bay, Ontario, Canada.","N/A"
"39728163","Photodynamic Therapy Using IR-783 Liposomes for Advanced Tongue and Breast Cancers in Humans.","2024 Dec 2","Kimura S, Hirasawa Y, Katagiri T","StateArt Inc., 2-9-12 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo 103-0012, Japan., StateArt Inc., 2-9-12 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo 103-0012, Japan., StateArt Inc., 2-9-12 Horidome-cho, Nihonbashi, Chuo-ku, Tokyo 103-0012, Japan.","N/A"
"39727016","Prognostic Performance of the Next-Generation Sequencing-Based Multigene Assay in Early Breast Cancer Patients Treated According to the 21-Gene Assay Results.","2024 Dec 23","Kim B, Chung W, Han W","DCGen Co. Ltd. Seoul, Korea., DCGen Co. Ltd. Seoul, Korea., DCGen Co. Ltd. Seoul, Korea.","N/A"
"39726796","Bayesian Latent Class Models for Evaluating the Validity of Claim-based Definitions of Disease Outcomes.","2024 Oct 1","N/A","Astellas Pharma Inc., Chuo-Ku, Tokyo, Japan.","N/A"
"39724260","Single-cell transcriptomes of dissecting the intra-tumoral heterogeneity of breast cancer microenvironment.","2024 Dec 26","Mao X, He T, Yang S","Clinical Research Institute, The First People's Hospital of Foshan, Foshan, 528100, China., Clinical Research Institute, The First People's Hospital of Foshan, Foshan, 528100, China., Clinical Research Institute, The First People's Hospital of Foshan, Foshan, 528100, China.","zhihaotsang@163.com"
"39723668","Clinical Proteomics Reveals Vulnerabilities in Noninvasive Breast Ductal Carcinoma and Drives Personalized Treatment Strategies.","2025 Jan 1","N/A","CancerCare Manitoba Research Institute, Winnipeg, Canada.","N/A"
"39723380","Whole exome-seq and RNA-seq data reveal unique neoantigen profiles in Kenyan breast cancer patients.","2024","Melly E","International Livestock Research Institute, Nairobi, Kenya.","N/A"
"39723363","Corrigendum: Radiotherapy and breast cancer: finally, an lncRNA perspective on radiosensitivity and radioresistance.","2024","Yazarlou F","Center for Childhood Cancer, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH, United States., Shenzhen Huayuan Biological Science Research Institute, Shenzhen Huayuan Biotechnology Co. Ltd., Shenzhen, China.","N/A"
"39723047","Drones and Workers of Honeybee Apis mellifera L. Dried Powder: Chemical Composition, Antioxidant, and Anticancer Assessment.","2024 Dec","Hussein AMS, Smuda SS","Research Institute of Food Science and Technology (RIFST) Mashhad Iran., Food Technology Department, Food Industries and Nutrition Research Institute National Research Centre Dokki Giza Egypt.","N/A"
"39720985","The evolving tumor-associated adipose tissue microenvironment in breast cancer: from cancer initiation to metastatic outgrowth.","2024 Dec 25","Jin L","Zhejiang Orient Gene Biotech Co., Ltd, Huzhou, 313300, China.","xczhou@ybu.edu.cn"
"39720971","Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor.","2024 Dec 25","Cuthbert D","Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, ON, Canada.","diego.malongimenez@uhn.ca"
"39720416","Prioritizing cases from a multi-institutional cohort for a dataset of pathologist annotations.","2025 Jan","Garcia V, Gardecki E, Lennerz J","U.S. Food and Drug Administration, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD, United States of America., U.S. Food and Drug Administration, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD, United States of America., U.S. Food and Drug Administration, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD, United States of America., U.S. Food and Drug Administration, Center for Devices and Radiological Health, Office of Science and Engineering Laboratories, Division of Imaging, Diagnostics, and Software Reliability, Silver Spring, MD, United States of America.","N/A"
"39720357","Preoperative Prediction of Breast Cancer Histological Grade Using Intratumoral and Peritumoral Radiomics Features from T2WI and DWI MR Sequences.","2024","Wu Q","Beijing United Imaging Research Institute of Intelligent Imaging & United Imaging Intelligence (Beijing) Co., Ltd, Beijing, People's Republic of China.","N/A"
"39718609","Gold nanoparticles mediate suppression of angiogenesis and breast cancer growth via MMP-9/NF-kappaB/mTOR and PD-L1/PD-1 signaling: integrative in vitro validation and network pharmacology insights.","2024 Dec 24","El-Sewedy T, El-Far AH","Higher Technological Institute of Applied Health Sciences, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt. dr.prof2011@gmail.com., Higher Technological Institute of Applied Health Sciences, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt.","dr.prof2011@gmail.com"
"39716933","Cytotoxic pregnane glycosides from Monolluma quadrangula (Forssk.).","2024 Dec 24","Mostafa ME","Plant Protection Research Institute, Agriculture Research Center, Giza, Egypt.","N/A"
"39715959","Nuclear receptor profiling for subtype classification and as prognostic markers in 33 cancer types.","2024 Dec 24","Suzuki H, Yamamoto Y, Nakayama J","Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan., Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan., Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan., Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan. jun.nakayama@oici.jp.","jun.nakayama@oici.jp"
"39715925","Author Correction: pi-HuB: the proteomic navigator of the human body.","2025 Jan","Faridi P","Advanced Clinical Biosystems Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA., The Scripps Research Institute, La Jolla, CA, USA.","hefc@bmi.ac.cn"
"39715910","Evaluation of BCRP-Related DDIs Between Methotrexate and Cyclosporin A Using Physiologically Based Pharmacokinetic Modelling.","2024 Dec 24","N/A","Simulations Plus, Inc., Lancaster, California, USA.","stephan.schaller@esqlabs.com"
"39711226","Personalized Multi-Epitope Nanovaccine Unlocks B Cell-Mediated Multiple Pathways of Antitumor Immunity.","2025 Feb","N/A","Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, 264000, China.","N/A"
"39709655","Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer: A systematic review and network meta-analysis.","2025 Jan","Schettini F, Pascual T, Martinez-Saez O","Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain. Electronic address: schettini@recerca.clinic.cat., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain., Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain; Medical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain; SOLTI Cancer Research Group, Barcelona, Spain.","schettini@recerca.clinic.cat"
"39707711","CDK4/6 inhibitor plus endocrine therapy for advanced breast cancer: results from a web-based survey in Japan.","2025 Feb","Xu L, Muramatsu Y","Access & Value, Pfizer Japan Inc, Tokyo, Japan., Oncology Medical Affairs, Pfizer Japan Inc, Tokyo, Japan.","N/A"
"39707483","Neonates exposed to HIV but uninfected exhibit an altered gut microbiota and inflammation associated with impaired breast milk antibody function.","2024 Dec 20","Byrne A, Maust BS, Feng C, Alinde BL","Seattle Children's Research Institute, Seattle, WA, USA., Seattle Children's Research Institute, Seattle, WA, USA., Seattle Children's Research Institute, Seattle, WA, USA., Seattle Children's Research Institute, Seattle, WA, USA., Seattle Children's Research Institute, Seattle, WA, USA., Seattle Children's Research Institute, Seattle, WA, USA. donaldnyangahu@gmail.com.","donaldnyangahu@gmail.com"
"39707454","Cilengitide sensitivity is predicted by overall integrin expression in breast cancer.","2024 Dec 20","N/A","Computational Biology Branch, National Library of Medicine and Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD, 20892, USA. augustin@nih.gov.","Nomeda_Girnius@hms.harvard.edu"
"39707103","Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.","2025 Feb","Lamont EB, Tarantino P, Ahlberg C, Qi J, Davi R","Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA. elizabeth.lamont@3ds.com., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA., Medidata AI, Medidata Solutions, a Dassault Systemes Company, 350 Hudson Street, New York, NY, 10014, USA.","elizabeth.lamont@3ds.com"
"39706915","Breast cancer brain metastases genomic profiling identifies alterations targetable by immune-checkpoint and PARP inhibitors.","2024 Dec 20","Sokol ES, Razis ED, Clark A, Huang RSP, Palmieri C","Foundation Medicine, Inc., Boston, MA, USA., Foundation Medicine, Inc., Boston, MA, USA., Foundation Medicine, Inc., Boston, MA, USA., Foundation Medicine, Inc., Boston, MA, USA., Foundation Medicine, Inc., Boston, MA, USA.","c.palmieri@liverpool.ac.uk"
"39706891","CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.","2024 Dec 21","Raninga PV, Vittorio O, Khanna KK","QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. Prahlad.Raninga@mater.uq.edu.au., Murdoch Children's Research Institute, 50 Flemington Road, Parkville, VIC, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia., QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, Brisbane, QLD, 4006, Australia. KumKum.Khanna@mater.edu.edu.au.","Prahlad.Raninga@mater.uq.edu.au"
"39706338","Prognostic value of residual disease (RD) biology and gene expression changes during the neoadjuvant treatment in patients with HER2-positive early breast cancer (EBC).","2024 Dec 18","Choudhury A","FTE of Novartis Healthcare Pvt. Ltd., Hyderabad, India.","lisa_carey@med.unc.edu"
"39706331","Web-Based Pain Coping Skills Training (PCST) for Managing Aromatase Inhibitor-Associated Arthralgia in Breast Cancer Survivors: Randomized Controlled Trial Protocol.","2025 Feb","Farrell D","People Designs, Inc., Durham, NC, United States of America.","Christine.rini@northwestern.edu"
"39705674","Prototype of an App Designed to Support Self-Management for Health Behaviors and Weight in Women Living With Breast Cancer: Qualitative User Experience Study.","2024 Dec 20","May CN, Mitchell ES, McCallum M, Michaelides A","Academic Research, Noom Inc, New York, NY, United States., Academic Research, Noom Inc, New York, NY, United States., Academic Research, Noom Inc, New York, NY, United States., Academic Research, Noom Inc, New York, NY, United States.","N/A"
"39705612","Insights into AI advances in immunohistochemistry for effective breast cancer treatment: a literature review of ER, PR, and HER2 scoring.","2025 Jan","Ahmed GN","North East Cancer Hospital and Research Institute, Guwahati, Assam, India.","N/A"
"39705237","Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.","2024","Parisi D","Information Management Services, Inc., Calverton, Maryland, United States of America.","N/A"
"39705151","Loss of RPN1 promotes antitumor immunity via PD-L1 checkpoint blockade in triple-negative breast cancer - experimental studies.","2025 Feb 1","Wang L","Chongqing Precision Medical Industry Technology Research Institute, Chongqing, China., Chongqing Precision Medical Industry Technology Research Institute, Chongqing, China.","N/A"
"39704751","Apoptotic and Molecular Mechanisms of Carthamidin in Breast Cancer Therapy: An Integrated In Vitro and In Silico Study.","2024 Dec 20","Saravanan KM","B-Aatral Biosciences Private Limited, Bangalore, Karnataka, 560091, India.","bupeshgiri@nagalanduniversity.ac.in"
"39704272","The effects of exercise on anxiety and depression in adults with cancer: A meta-review of meta-analyses.","2024 Dec 20","N/A","Fralin Biomedical Research Institute, Virginia Tech Carilion, Roanoke, VA, USA.","N/A"
"39703347","Digital breast tomosynthesis system concept addressing the needs in breast cancer screening and diagnosis.","2025 Jan","Klinnert T","Siemens Medical Solutions USA Inc., Malvern, Pennsylvania, United States.","N/A"
"39703140","Comparative Analysis of the Therapeutic Potential of Extracellular Vesicles Secreted by Aged and Young Bone Marrow-Derived Mesenchymal Stem Cells in Osteoarthritis Pathogenesis.","2024 Dec 20","Batra J","Cancer Single Cell Genomics Laboratory, Translational Breast Cancer Program, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia.","N/A"
"39702881","Galangin promotes apoptosis by upregulating the pro-apoptotic gene BAX in triple-negative breast cancer.","2024 Dec 20","Dilip A","Institute Of Applied Biological Research and Development, a Division of, Nirav BioSolutions Pvt Ltd , Aundh, Pune, India.","drvaibhavladke@gmail.com"
"39702630","Methodological issues in radiomics: impact on accuracy of MRI for predicting response to neoadjuvant chemotherapy in breast cancer.","2024 Dec 19","Rizzo G, Jereczek-Fossa BA","Institute of Biomedical Technologies, Segrate, Italy., Institute of Intelligent Industrial Systems and Technologies for Advanced Manufacturing, Milan, Italy.","sofia.netti@ieo.it"
"39702409","Screening for breast cancer: a systematic review update to inform the Canadian Task Force on Preventive Health Care guideline.","2024 Dec 19","Yaffe M, Moher D","Physical Sciences Program, Sunnybrook Research Institute and Ontario Institute for Cancer Research, Toronto, ON, Canada., Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada.","d.bennett@uottawa.ca"
"39701264","Immunotherapeutic effects of de novo benzimidazole derivative and prebiotic bacterial levan against triple-negative breast tumors by harnessing the immune landscape to intercept the oncogenic transcriptome.","2025 Feb","Shawky H, Fayed DB, Abd El-Karim SS, Esawy MA, Farrag EK","Therapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki 12622, Cairo, Egypt. Electronic address: hs.tohami@nrc.sci.eg., Therapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki 12622, Cairo, Egypt., Therapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki 12622, Cairo, Egypt., Chemistry of Natural and Microbial Products Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki 12622, Cairo, Egypt., Therapeutic Chemistry Department, Pharmaceutical Industries and Drug Research Institute, National Research Centre, Dokki 12622, Cairo, Egypt.","hs.tohami@nrc.sci.eg"
"39700441","Implementation of Universal Germline Genetic Testing Into Standard of Care for Patients With Prostate Cancer: The Time Is Now.","2024 Dec 19","Nielsen SM, Esplin ED","Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA., Labcorp Genetics Inc (formerly Invitae Corp), San Francisco, CA.","N/A"
"39700137","ACSL4-mediated H3K9 and H3K27 hyperacetylation upregulates SNAIL to drive TNBC metastasis.","2024 Dec 24","Sinha A, Saini KK, Khan MA, Satrusal SR, Verma A, Rai P, Meena S, Singh MP, Vasudevan M, Singhai A, Singh K, Mishra AK, Kamat SS","Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India., Theomics International Pvt Ltd., Bangalore 560043, India., Theomics International Pvt Ltd., Bangalore 560043, India., Division of Cancer Biology, Council of Scientific & Industrial Research-Central Drug Research Institute, Lucknow 226031, India.","N/A"
"39699296","Technological innovations in margarine production: Current trends and future perspectives on trans-fat removal and saturated fat replacement.","2025 Jan","Bihola A, Chaudhary MB","Dairy Technology Division, ICAR-National Dairy Research Institute, Karnal, Haryana, India., ICAR-Indian Agricultural Research Institute, Assam, India.","N/A"
"39698270","Developing MYC Degraders Bearing the Von Hippel-Lindau Ligand to Target the ""Undruggable"" MYC.","2024 Dec 13","Karra AV, Politou AS, Sarli V","Biomedical Research Institute, Foundation for Research and Technology, Ioannina 45110, Greece., Biomedical Research Institute, Foundation for Research and Technology, Ioannina 45110, Greece., Biomedical Research Institute, Foundation for Research and Technology, Ioannina 45110, Greece., Biomedical Research Institute, Foundation for Research and Technology, Ioannina 45110, Greece.","N/A"
"39697231","The role of FDG PET assessment in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 inhibitors in the second-line setting.","2024","Kubeczko M, Polakiewicz-Gilowska A, Swiderska K, Chmielik E, Jarzab M","Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland., Breast Cancer Center, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, Poland.","N/A"
"39696026","Changes in essential cancer medicines and association with cancer outcomes: an observational study of 158 countries.","2024 Dec 18","Ul Haq MZ, Heredia C, Buadu A, Rizvi A, Workentin A, Persaud N","MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada., MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada., MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada., MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada., MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada., MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Unity Health Toronto, 209 Victoria St, Toronto, ON, M5B 1T8, Canada. nav.persaud@utoronto.ca.","nav.persaud@utoronto.ca"
"39695334","Women's perspectives of molecular breast imaging: a qualitative study.","2025 Feb","Graziadio S, Powell T, Bray A","NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle upon Tyne, UK., NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle upon Tyne, UK., NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle upon Tyne, UK., NIHR Newcastle In Vitro Diagnostics Co-operative, Newcastle upon Tyne, UK.","helen.elliott13@nhs.net"
"39694990","Time to deterioration of patient-reported outcome endpoints in cancer clinical trials: targeted literature review and best practice recommendations.","2024 Dec 18","Cocks K, Sims J, Worthy G, Stein J, Ayala-Nunes L","Adelphi Values Ltd, Patient-Centered Outcomes, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, UK. kim.cocks@adelphivalues.com., Adelphi Values Ltd, Patient-Centered Outcomes, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, UK., Adelphi Values Ltd, Patient-Centered Outcomes, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, UK., Adelphi Values Ltd, Patient-Centered Outcomes, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, UK., Adelphi Values Ltd, Patient-Centered Outcomes, Adelphi Mill, Grimshaw Lane, Bollington, Macclesfield, SK10 5JB, UK.","kim.cocks@adelphivalues.com"
"39694573","Patient-reported quality of life in Asian patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial.","2024 Dec 19","Reisman A, Zhao H, Shen J, Broughton E","Global Value and Evidence, Pfizer Inc, New York, NY, 10001, USA., Pfizer Inc, Shanghai 201203, China., Pfizer Inc, Shanghai 201203, China., Global Value and Evidence, Pfizer Inc, New York, NY, 10001, USA.","N/A"
"39693591","Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.","2024 Dec 18","Hamilton E, Munoz M","Sarah Cannon Research Institute, Nashville, TN., Hospital Clinic and Translational Genomics and Targeted Therapeutics, Institut d'Investigacions Biomediques Pi I Sunyer-IDIBAPS, Barcelona, Spain.","N/A"
"39689721","Deployment of a Machine Learning Algorithm in a Real-World Cohort for Quality Control Monitoring of Human Epidermal Growth Factor-2-Stained Clinical Specimens in Breast Cancer.","2024 Dec 18","Glass B, Vandenberghe ME, Chavali ST, Javed SA, Resnick M, Pokkalla H, Elliott H, Rao S, Sridharan S, Brosnan-Cashman JA, Wapinski I, Montalto M, Beck AH, Barker C","From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California., From PathAI, Boston, Massachusetts (Glass, Chavali, Javed, Resnick, Pokkalla, Elliott, Rao, Sridharan, Brosnan-Cashman, Wapinski, Montalto, Beck); and Precision Medicine and Biosamples, Oncology R&D, AstraZeneca, Cambridge, United Kingdom (Vandenberghe, Barker). Chavali is currently affiliated at Analog Devices, Wilmington, Massachusetts. Resnick is currently affiliated at Rhode Island Hospital and The Miriam Hospital, Providence, Rhode Island. Elliott is currently affiliated at BigHat Biosciences, San Mateo, California. Rao is currently affiliated at Seton Medical Center, Daly City, California. Sridharan is currently affiliated at Verily, South San Francisco, California. Wapinski is currently affiliated at Sanofi Pharmaceuticals, Cambridge, Massachusetts. Montalto is currently affiliated at Amgen, Thousand Oaks, California.","N/A"
"39689267","Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits.","2025 Mar","Autier P","Philippe Autier, MD, PhD, International Prevention Research Institute, Lyon, France.","N/A"
"39688838","Concurrent Detection of Protein and miRNA at the Single Extracellular Vesicle Level Using a Digital Dual CRISPR-Cas Assay.","2025 Jan 14","Lu Y, Cheng J","Iomics Biosciences, Beijing 101318, China., Iomics Biosciences, Beijing 101318, China.","N/A"
"39687477","Clinical Implementation of Cone Beam Computed Tomography-Guided Online Adaptive Radiation Therapy in Whole Breast Irradiation.","2025 Jan","Admiraal MA","Varian Medical Systems, Radiotherapy Solutions, Palo Alto, California.","N/A"
"39687472","The Impact of Synchrotron Microbeam Radiation Therapy Combined With Broad Beam in a Preclinical Breast Cancer Model.","2025 Jan","Balderstone I, Brunt K, Dietler BB","Olivia Newton-John Cancer Research Institute (ONJCRI), Heidelberg, Victoria, Australia., Olivia Newton-John Cancer Research Institute (ONJCRI), Heidelberg, Victoria, Australia., XRV Medical Pty Ltd, Geelong North, Victoria, Australia., Olivia Newton-John Cancer Research Institute (ONJCRI), Heidelberg, Victoria, Australia.","N/A"
"39686895","[NDRG1 protein expression in breast cancer samples, relationship with lymph nodes metastasis].","2024","Mikhaleva LM","Avtsyn Research Institute of Human Morphology of Petrovsky National Research Centre of Surgery, Moscow, Russia.","N/A"
"39686815","Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer.","2025 Feb","Han S","Endocrine Research Institute, Severance Hospital, Seoul, South Korea.","N/A"
"39686656","Challenges and barriers for the adoption of personalized medicine in Europe: the case of Oncotype DX Breast Recurrence Score((R)) test.","2024 Dec 17","Van Den Bulcke M","Amgen Inc, 20 W Manilla Ave, Pittsburgh, PA, USA., Sarah Cannon Research Institute, Nashville, TN, USA.","N/A"
"39684741","Metabolomics-Based Machine Learning Models Accurately Predict Breast Cancer Estrogen Receptor Status.","2024 Dec 4","Haince JF, Bux RA, Huang G, Tappia PS, Ramjiawan B, Ford WR","BioMark Diagnostic Solutions Inc., Quebec, QC G1K 3G5, Canada., BioMark Diagnostics Inc., Richmond, BC V6X 2W2, Canada., BioMark Diagnostic Solutions Inc., Quebec, QC G1K 3G5, Canada., BioMark Diagnostics Inc., Richmond, BC V6X 2W2, Canada., Asper Clinical Research Institute, Winnipeg, MB R2H2A6, Canada., Asper Clinical Research Institute, Winnipeg, MB R2H2A6, Canada.","N/A"
"39682230","A Global Regional Comparison of the Risk of Breast Cancer in Woman Using Oral Contraceptives-Systematic Review and Meta-Analysis.","2024 Dec 2","Borowska M","Cancer Epidemiology and Primary Prevention Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.","N/A"
"39682219","Predictive Modeling of Long-Term Survivors with Stage IV Breast Cancer Using the SEER-Medicare Dataset.","2024 Dec 1","Adam N","Phalcon, LLC, Manhasset, NY 11030, USA.","N/A"
"39681325","scPAS: single-cell phenotype-associated subpopulation identifier.","2024 Nov 22","Wang Z","Genetron Health (Beijing) Co. Ltd, 1-2/F, Building 11, Zone 1, 8 Life Science Parkway, Changping District, Beijing 102208, China.","N/A"
"39680314","Correlation Between Disease-Free Survival Endpoints and Overall Survival in Elderly Patients with Early-Stage HER2-Negative Breast Cancer: A SEER-Medicare Analysis.","2025 Feb","Earla JR, Kponee-Shovein K, Mahendran M, Song Y, Hua Q, Hilts A, Sun Y, Hirshfield KM, Mejia JA","Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ, 07065, USA. jagadeswara.rao.earla@merck.com., Analysis Group, Inc, Boston, MA, USA., Analysis Group, Inc, Boston, MA, USA., Analysis Group, Inc, Boston, MA, USA., Analysis Group, Inc, Boston, MA, USA., Analysis Group, Inc, Boston, MA, USA., Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ, 07065, USA., Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ, 07065, USA., Merck & Co., Inc., 90 E Scott Ave, Rahway, NJ, 07065, USA.","jagadeswara.rao.earla@merck.com"
"39679660","New Arylalkenyl alpha-Pyrones from Cryptocarya densiflora.","2024 Dec 16","Miao L, Zhang Y","Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, P. R. China., Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, P. R. China., Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai, P. R. China.","N/A"
"39679653","MiRNA in archival serum samples derived from breast cancer patients treated with neoadjuvant chemotherapy vs freshly collected samples: Pilot study.","2024 Dec 16","Kubeczko M, Tudrej P, Tyszkiewicz T, Krzywon A, Oczko-Wojciechowska M, Jarzab M","Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland., Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland., Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland., Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland., Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland., Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.","N/A"
"39678425","A preliminary study on the diagnostic value of contrast-enhanced ultrasound and micro-flow imaging for detecting blood flow signals in breast cancer patients.","2024 Nov 30","Wang H","Zhejiang CuraWay Medical Technology Co., Ltd., Hangzhou, China.","N/A"
"39676564","Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey.","2025 Feb","Aguiar-Ibanez R, McQuarrie K","Merck Canada Inc., Kirkland, QC, Canada., Merck & Co., Inc., Rahway, NJ, USA.","N/A"
"39676429","Advances of New Extracellular Vesicle Isolation and Detection Technologies in Cancer Diagnosis.","2024 Dec 15","N/A","Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Ningbo, Zhejiang, 315010, China., Zhejiang Engineering Research Center of Innovative Technologies and Diagnostic and Therapeutic Equipment for Urinary System Diseases, Ningbo, Zhejiang, 315010, China.","N/A"
"39675974","Cardiovascular adverse events in patients with HER2-positive breast cancer treated with trastuzumab-drug conjugates : a Bayesian disproportional real world study for signal detection leveraging the FDA Adverse Event Reporting System (FAERS).","2024 Dec 17","Hu J, Chen S, Jia H, Cai N, Guan Y","Guangdong Provincial Biotechnology Research Institute (Guangdong Provincial Laboratory Animals Monitoring Center), Guangzhou, Guangdong, China., Guangdong Provincial Biotechnology Research Institute (Guangdong Provincial Laboratory Animals Monitoring Center), Guangzhou, Guangdong, China., Guangdong Provincial Biotechnology Research Institute (Guangdong Provincial Laboratory Animals Monitoring Center), Guangzhou, Guangdong, China., Guangdong Provincial Biotechnology Research Institute (Guangdong Provincial Laboratory Animals Monitoring Center), Guangzhou, Guangdong, China., Guangdong Provincial Biotechnology Research Institute (Guangdong Provincial Laboratory Animals Monitoring Center), Guangzhou, Guangdong, China.","N/A"
"39656887","Meta learning for mutant HLA class I epitope immunogenicity prediction to accelerate cancer clinical immunotherapy.","2024 Nov 22","Zhang X, Yang T","Postdoctoral Program of Heilongjiang Hengxun Technology Co., Ltd., Xuefu Road, 150090 Harbin, China., Shandong Hengxun Technology Co., Ltd., Miaoling Road, 266100 Qingdao, China.","N/A"
"39673402","Public assistance and survival equality in patients with EGFR mutation-positive lung cancer.","2025 Mar 5","Fujimura Y, Hayashi M, Ohtaki M, Otani K","Tokushukai Information System Inc., Kita-ku, Osaka 530-0001, Japan., Mirai Iryo Research Center Inc., Chiyoda-ku, Tokyo 102-0083, Japan., deCult Co., Ltd., Hatsukaichi-shi, Hiroshima 739-0413, Japan., deCult Co., Ltd., Hatsukaichi-shi, Hiroshima 739-0413, Japan.","N/A"
"39672514","Concurrent Versus Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual Triple-Negative Breast Cancer After Neoadjuvant-Chemotherapy: A Multicenter Comparative Study.","2024 Dec 11","Kim TH","Proton Therapy Center, Research Institute and Hospital, National Cancer center, Gyeonggi-do, Republic of Korea.","radiat@snu.ac.kr"
"39671272","Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial.","2025 Feb 25","Zhu X, Wang Z, Fan L, Shao ZM","Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China., Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.","N/A"
"39670857","Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody-Drug Radioconjugate.","2025 Feb 17","N/A","Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada., Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada., Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada., Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada., Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada., Canadian Nuclear Laboratories, Radiobiology and Health Branch, Chalk River, Canada.","N/A"
"39670797","TBK1 Reprograms Metabolism in Breast Cancer: An Integrated Omics Approach.","2025 Jan 3","Chellappan SP","Proteomics and Metabolomics Core, H. Lee Moffitt Cancer Center and Research Institute, 12902 USF Magnolia Drive, Tampa, Florida 33612, United States.","N/A"
"39670056","Radiobiology and modelling in Brachytherapy: A review inspired by the ESTRO Brachytherapy pre-meeting course.","2025 Jan","N/A","The Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.","N/A"
"39669603","Feasibility of an electronic patient-facing cancer family history tool in medically underserved populations.","2024","Bulkley J","Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, WA., Treuman Katz Center for Pediatric Bioethics, Seattle Children's Research Institute, Seattle, WA.","N/A"
"39669476","Lymphovascular Tumoral Emboli in Inflammatory Breast Cancer Result from Haptotaxis-Mediated Encircling Lymphangiogenesis.","2024 Dec","Hoffman RM","AntiCancer, Inc., 7917 Ostow St., Suite B, San Diego, CA 92111, USA.","N/A"
"39668131","Development and Characterization of a High-Affinity Selective Galectin-3 Mouse Tool Compound in Mouse Models of Cancer.","2024 Dec 26","Peterson K, Nilsson UJ, Holyer I, Jansson K, Roper JA, Slack RJ, Wachenfeldt HV, Zetterberg FR","Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, SE-413 46 Gothenburg, Sweden., Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, SE-413 46 Gothenburg, Sweden., Galecto Biotech AB, Cobis Science Park, Ole Maaloes Vej 3, DK-2200, Copenhagen, Denmark., Galecto Biotech ApS, Stevenage Bioscience Catalyst, Stevenage, Hertfordshire SG1 2FX, U.K., Galecto Biotech ApS, Nine Edinburgh Bioquarter, 9 Little France Road, Edinburgh EH16 4UX, U.K., Galecto Biotech ApS, Stevenage Bioscience Catalyst, Stevenage, Hertfordshire SG1 2FX, U.K., Galecto Biotech ApS, Stevenage Bioscience Catalyst, Stevenage, Hertfordshire SG1 2FX, U.K., Galecto Biotech AB, Cobis Science Park, Ole Maaloes Vej 3, DK-2200, Copenhagen, Denmark., Galecto Biotech AB, Sahlgrenska Science Park, Medicinaregatan 8 A, SE-413 46 Gothenburg, Sweden.","N/A"
"39668008","Plasma-free Amino Acid Profile is Beneficial for Breast Cancer Screening in Women With Dense Breasts.","2025 Feb","Yamamoto H, Kikuchi S","Ajinomoto Co. Inc, Kawasaki, Kanagawa, Japan., Ajinomoto Co. Inc, Kawasaki, Kanagawa, Japan.","tishik55@gmail.com"
"39667819","Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","2025 Feb","N/A","Medical Affairs, Astellas Pharma, Northbrook, Illinois., Global Development, Astellas Pharma, Northbrook, Illinois.","N/A"
"39666930","Clinical Utility of Genomic Sequencing for Hereditary Cancer Syndromes: An Observational Cohort Study.","2024 Dec","N/A","Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, Sinai Health, Toronto, ON, Canada.","N/A"
"39666881","Process of development of decentralised clinical trial methodology for cancer clinical trials in Aotearoa New Zealand.","2024 Dec 13","Dzhelali M","Research Manager, Medical Research Institute of New Zealand, Wellington, Aotearoa New Zealand.","N/A"
"39666368","The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response.","2025 Mar 4","Reparaz D, Celias DP, Entrialgo-Cadierno R, Alignani D, Pio R","Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain., Navarra's Health Research Institute (IDISNA), Pamplona, Spain.","N/A"
"39666132","Editorial Expression of Concern: Induction of HRR genes and inhibition of DNMT1 is associated with anthracycline anti-tumor antibiotic-tolerant breast carcinoma cells.","2024 Dec 12","Roychoudhury S","Saroj Gupta Cancer Center and Research Institute, MG Road, Thakurpukur, Kolkata, India.","ckpanda.cnci@gmail.com"
"39665251","The cost-effectiveness of treatment for high-risk, early-stage, triple-negative breast cancer in Egypt: an analysis of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant single-agent pembrolizumab.","2025 Dec","Haiderali A, Huang M","Center for Outcomes Research and Health Economy, Merck & Co., Inc, Rahway, NJ, USA., Center for Outcomes Research and Health Economy, Merck & Co., Inc, Rahway, NJ, USA.","N/A"
"39664242","Correction: Reinvestigation of Passerini and Ugi scaffolds as multistep apoptotic inducers via dual modulation of caspase 3/7 and P53-MDM2 signaling for halting breast cancer.","2024 Dec 10","Abu-Serie MM","Medical Biotechnology Department, Genetic Engineering and Biotechnology Research Institute, City of Scientific Research and Technological Applications (SRTA-City) Egypt.","mohammedsalahayoup@gmail.com"
"39664178","Case report: Prolonged benefit of ESG401, a Trop2 antibody-drug conjugate, in endocrine-refractory hormone receptor-positive, HER-2 negative metastatic breast cancer.","2024","N/A","Shanghai Escugen Biotechnology Co., Ltd, Shanghai, China.","N/A"
"39663494","pi-HuB: the proteomic navigator of the human body.","2024 Dec","Faridi P","Advanced Clinical Biosystems Research Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA., The Scripps Research Institute, La Jolla, CA, USA.","hefc@bmi.ac.cn"
"39663357","Cancer and disease profiles for PTEN pathogenic variants in Japanese population.","2025 Mar","Kohno T, Yoshida T","Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan., Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.","momozawa@riken.jp"
"39663171","Text message intervention delivered from Australian general practices to improve breast cancer survivors' physical activity and cardiovascular risk factors: protocol for the EMPOWER-SMS-GP effectiveness implementation randomised controlled trial.","2024 Dec 11","Raeside R","ANZAC Research Institute, Concord Repatriation General Hospital, Concord, New South Wales, Australia.","anna.singleton@sydney.edu.au"
"39663166","Prediction of relative survival trends in patients with cutaneous squamous cell carcinoma using a model-based period analysis: a retrospective analysis of the surveillance, epidemiology, and end results database.","2024 Dec 11","Deng L","Shanghai Aige Medical Beauty Clinic Co., Ltd. (Agge), Shanghai, China LiehuaDeng@126.com lyujun2020@jnu.edu.cn 3126832945@qq.com.","LiehuaDeng@126.com"
"39662889","Social risk factors and cancer prevention care among patients in community health-care settings.","2024 Nov 1","O'Malley J, Gold R","OCHIN, Inc, Portland, OR 97228, United States., OCHIN, Inc, Portland, OR 97228, United States., Center for Health Research, Kaiser Permanente Northwest, OCHIN, Inc, Portland, OR 97227, United States.","N/A"
"39661920","Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials.","2024 Dec 11","Kier M, Marron TU","Arvinas, Inc., Parthenon Therapeutics., GlaxoSmithKline, Inc.","N/A"
"39661553","Recurrence patterns-analysis from a South Indian breast cancer patient cohort.","2024 Dec 12","Gunda A, Bakre MM","OncoStem Diagnostics Private Limited, 4, Raja Ram Mohan Roy Road, Aanand Towers, Bangalore, Karnataka, India., OncoStem Diagnostics Private Limited, 4, Raja Ram Mohan Roy Road, Aanand Towers, Bangalore, Karnataka, India.","N/A"
"39661316","Correction: Population Pharmacokinetic Analysis of Tucatinib in Healthy Participants and Patients with Breast Cancer or Colorectal Cancer.","2025 Jan","Zhang D, Endres CJ","Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA., Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA., Pfizer Inc., 21717 30th Dr SE, Bothell, WA, 98021, USA. Ariel.Erickson@pfizer.com.","Ariel.Erickson@pfizer.com"
"39659779","Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy.","2024","Choi JW, Jain M, Locke FL","Clinical Research, Kite Pharma, a Gilead Company, Santa Monica, CA, United States., Clinical Research, Kite Pharma, a Gilead Company, Santa Monica, CA, United States., Clinical Research, Kite Pharma, a Gilead Company, Santa Monica, CA, United States.","N/A"
"39658552","Author Correction: Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation.","2024 Dec 10","N/A","ZJU-QILU Joint Research Institute, Hangzhou, Zhejiang, 310058, China. linaifu@zju.edu.cn.","lixu@westlake.edu.cn"
"39658449","Corrigendum to ""Combination of MAPK inhibition with photothermal therapy synergistically augments the anti-tumor efficacy of immune checkpoint blockade"" [Journal of Controlled Release 332 (2021) 194-209].","2025 Jan 10","Chen B","Conmed Biosciences Inc, 610200 Chengdu, Sichuan, China.","shihb@scu.edu.cn"
"39658029","Assessing Tissue Dielectric Constant Values in Tumor Bearing and Healthy Breasts.","2025 Feb","Tomaselli MB","Gentle Touch Breast Diagnostics, Coral Springs, Florida, USA.","N/A"
"39657819","Identification and characterization of host miRNAs that target the mouse mammary tumour virus (MMTV) genome.","2024 Dec","N/A","ASPIRE Research Institute in Precision Medicine, Abu Dhabi, UAE., ASPIRE Research Institute in Precision Medicine, Abu Dhabi, UAE.","N/A"
"39657447","Domain generalization for mammographic image analysis with contrastive learning.","2025 Feb","Lei C, Ouyang X, Cheng JZ","Shanghai United Imaging Intelligence Co., Ltd., Shanghai 200030, China., Shanghai United Imaging Intelligence Co., Ltd., Shanghai 200030, China., Shanghai United Imaging Intelligence Co., Ltd., Shanghai 200030, China. Electronic address: jzcheng@ntu.edu.tw.","jzcheng@ntu.edu.tw"
